[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 492
1. Gotohda N, Ishii H, Konishi M, Nakagohri T, Takahashi S, Furuse J, Yoshino M, Kinoshita T: Selection criteria for reduction hepatectomy in multiple advanced hepatocellular carcinoma. Anticancer Res; 2006 Nov-Dec;26(6C):4671-4
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selection criteria for reduction hepatectomy in multiple advanced hepatocellular carcinoma.
  • BACKGROUND: Few studies have compared the prognostic impact of reduction hepatectomy (RH) for advanced hepatocellular carcinoma (HCC) with that of non-surgical treatment or curative hepatectomy.
  • CONCLUSION: RH could be recommended to patients with multiple advanced HCC extending to >50% of the whole liver.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Hepatectomy. Humans. Male. Middle Aged. Patient Selection. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17214325.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


2. Yin XY, Lü MD, Liang LJ, Lai JM, Li DM, Kuang M: Systemic chemo-immunotherapy for advanced-stage hepatocellular carcinoma. World J Gastroenterol; 2005 Apr 28;11(16):2526-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic chemo-immunotherapy for advanced-stage hepatocellular carcinoma.
  • AIM: To evaluate the therapeutic efficacy of systemic chemo-immunotherapy for advanced hepatocellular carcinoma (HCC).
  • METHODS: Twenty-six patients with advanced HCC were treated by using systemic chemo-immunotherapy (PIAF regimen), which consisted of cisplatin (20 mg/m2) intravenously daily for 4 consecutive day, doxorubicin (40 mg/m2) intravenously on day 1, 5-fluorouracil (400 mg/m2) intravenously daily for 4 consecutive day, and human recombinant alpha-interferon-2a (5 MU/m2) subcutaneous injection daily for 4 consecutive day.
  • CONCLUSION: Systemic chemo-immunotherapy using PIAF regimen represented an effective treatment and could improve the survival rate and prolong the survival time in selected patients with advanced HCC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Hepatocellular / drug therapy. Cisplatin / administration & dosage. Doxorubicin / administration & dosage. Fluorouracil / administration & dosage. Interferon-alpha / administration & dosage. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Recombinant Proteins. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15832431.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Recombinant Proteins; 80168379AG / Doxorubicin; 99210-65-8 / interferon alfa-2b; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; PIAF regimen
  • [Other-IDs] NLM/ PMC4305648
  •  go-up   go-down


3. Schwartz JD, Sung M, Schwartz M, Lehrer D, Mandeli J, Liebes L, Goldenberg A, Volm M: Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha2a upon progression. Oncologist; 2005 Oct;10(9):718-27
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha2a upon progression.
  • PURPOSE: To evaluate thalidomide in advanced hepatocellular carcinoma (HCC) and to evaluate combined thalidomide and low-dose interferon-alpha2a (IFN-alpha2a) after tumor progression on thalidomide.
  • CONCLUSIONS: Thalidomide is not well tolerated and confers limited disease control in advanced HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / drug therapy. Interferon-alpha / administration & dosage. Liver Neoplasms / drug therapy. Thalidomide / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cytokines / blood. Disease Progression. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Recombinant Proteins

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16249352.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA90584; United States / NIDDK NIH HHS / DK / DK60498; United States / NCI NIH HHS / CM / N01-CM-17103
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interferon-alpha; 0 / Recombinant Proteins; 4Z8R6ORS6L / Thalidomide; 76543-88-9 / interferon alfa-2a
  •  go-up   go-down


Advertisement
4. Yau T, Pang R, Chan P, Poon RT: Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib. Expert Opin Pharmacother; 2010 Sep;11(13):2187-98
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.
  • IMPORTANCE OF THE FIELD: With the recent advances in the knowledge of molecular biology of hepatocellular carcinoma (HCC), there have been encouraging developments in targeted therapy for advanced HCC.
  • AREAS COVERED IN THIS REVIEW: This review discusses the development of targeted therapy for advanced HCC patient since 2006.
  • Pure anti-angiogenic agents such as bevacizumab and PTK 787 demonstrate modest activity in treating patients with advanced HCC.
  • Sorafenib, a multi-targeted tyrosine kinase inhibitor with both anti-angiogenic and anti-proliferative effects, has been shown to prolong the overall survival of patients with advanced HCC in two Phase III randomized trials.
  • WHAT THE READER WILL GAIN: After reading this review, the reader should have an in-depth understanding of the latest developments in the molecular targeted therapy of advanced HCC.
  • TAKE HOME MESSAGE: The development of sorafenib in the treatment of advanced HCC proves the concept that molecular targeted therapies, especially anti-angiogenic agents, play a pivotal role in the treatment of this otherwise chemoresistant neoplasm.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Molecular Targeted Therapy. Pyridines / therapeutic use
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clinical Trials as Topic. Disease Progression. Female. Humans. Male. Niacinamide / analogs & derivatives. Phenylurea Compounds. Protein Kinase Inhibitors / therapeutic use. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20707757.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


5. Kawamura Y, Ikeda K, Kumada H: [Strategy for advanced hepatocellular carcinoma unresponsive to transcatheter arterial chemoembolization using epirubicin]. Gan To Kagaku Ryoho; 2010 Mar;37(3):402-7
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Strategy for advanced hepatocellular carcinoma unresponsive to transcatheter arterial chemoembolization using epirubicin].
  • Transcatheter arterial chemoembolization (TACE) has been reported to be an effective palliative treatment for patients with unresectable hepatocellular carcinoma (HCC), and many chemotherapeutic agents such as epirubicin and mitomycin C were used with lipiodol in Japan.
  • In this report, we retrospectively studied 152 consecutive patients with advanced HCC resistant to TACE using epirubicin, and all cases were treated with platinum derivatives using transcatheter arterial chemotherapy.
  • A number of molecular-based chemotherapeutic agents are expected to become available in the future, and the primary therapy of advanced stage HCC may change with the introduction of these drugs.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Platinum Compounds / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibiotics, Antineoplastic / administration & dosage. Chemoembolization, Therapeutic. Drug Resistance, Neoplasm. Epirubicin / administration & dosage. Female. Humans. Male. Middle Aged. Survival Rate

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20332675.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 0 / Platinum Compounds; 3Z8479ZZ5X / Epirubicin
  •  go-up   go-down


6. Cosme A, Montalvo I, Sánchez J, Ojeda E, Torrado J, Zapata E, Bujanda L, Gutiérrez A, Arenas I: [Type III glycogen storage disease associated with hepatocellular carcinoma]. Gastroenterol Hepatol; 2005 Dec;28(10):622-5
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Type III glycogen storage disease associated with hepatocellular carcinoma].
  • [Transliterated title] Glucogenosis tipo III asociada a carcinoma hepatocelular.
  • We present the case of a 31-year-old woman, diagnosed in childhood with type III glycogen storage disease, who 30 years after onset developed a hepatocellular carcinoma with portal thrombosis in the context of advanced cirrhosis.
  • This is the first case to be reported in the Spanish literature of type III glycogen storage disease associated with hepatocellular carcinoma.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Liver Neoplasms / etiology
  • [MeSH-minor] Adult. Ascites / etiology. Biomarkers, Tumor / blood. Disease Progression. Fatal Outcome. Female. Glycogen Storage Disease Type III / complications. Humans. Liver Cirrhosis / etiology. Neoplasm Proteins / blood. alpha-Fetoproteins / analysis

  • Genetic Alliance. consumer health - Glycogen Storage Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16373012.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / alpha-Fetoproteins
  •  go-up   go-down


7. Seo YS, Kim JN, Keum B, Park S, Kwon YD, Kim YS, Jeen YT, Chun HJ, Kim CY, Kim CD, Ryu HS, Um SH: Radiotherapy for 65 patients with advanced unresectable hepatocellular carcinoma. World J Gastroenterol; 2008 Apr 21;14(15):2394-400
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy for 65 patients with advanced unresectable hepatocellular carcinoma.
  • AIM: To evaluate the efficacy of radiotherapy (RT) in patients with advanced unresectable hepatocellular carcinoma (HCC).
  • CONCLUSION: RT is effective in treating advanced HCC with a tumor response rate of 56.9%.
  • [MeSH-major] Carcinoma, Hepatocellular / radiotherapy. Liver Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Radiotherapy / adverse effects. Risk Assessment. Severity of Illness Index. Time Factors. Treatment Outcome. alpha-Fetoproteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 May 1;47(2):435-42 [10802371.001]
  • [Cites] Hepatology. 2005 Nov;42(5):1208-36 [16250051.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jul 15;47(5):1331-5 [10889387.001]
  • [Cites] Strahlenther Onkol. 2000 Sep;176(9):406-10 [11050913.001]
  • [Cites] J Hepatol. 2001 Sep;35(3):421-30 [11592607.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):150-5 [12182985.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Feb 1;55(2):329-36 [12527045.001]
  • [Cites] World J Gastroenterol. 2003 Sep;9(9):1885-91 [12970869.001]
  • [Cites] Clin Oncol. 1979 Mar;5(1):25-31 [217565.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 Jan;12(1):31-5 [3080390.001]
  • [Cites] Cancer. 1987 Sep 15;60(6):1194-203 [2441837.001]
  • [Cites] Arch Surg. 1989 Sep;124(9):1025-8 [2549912.001]
  • [Cites] Surgery. 1989 Oct;106(4):740-8; discussion 748-9 [2799650.001]
  • [Cites] Surgery. 1990 May;107(5):511-20 [2159190.001]
  • [Cites] Cancer. 1991 Nov 15;68(10):2150-4 [1655202.001]
  • [Cites] Cancer. 1992 Feb 15;69(4):920-4 [1370918.001]
  • [Cites] Cancer. 1993 Jan 1;71(1):62-5 [8380123.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1286-93 [8391066.001]
  • [Cites] J Clin Oncol. 1994 Jun;12(6):1204-11 [8201383.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1237-48 [7713785.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):42-6 [7740809.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Dec 1;39(5):1077-85 [9392547.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jan 15;43(2):393-7 [10030267.001]
  • [Cites] J Gastroenterol Hepatol. 1999 Oct;14(10):941-5 [10530488.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1965 Jan;93:200-8 [14243011.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1143-50 [15752895.001]
  • [Cites] World J Gastroenterol. 2005 Mar 21;11(11):1697-9 [15786553.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(11):2210-8 [10829040.001]
  • (PMID = 18416468.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / AFP protein, human; 0 / alpha-Fetoproteins
  • [Other-IDs] NLM/ PMC2705096
  •  go-up   go-down


8. Huitzil-Melendez FD, Capanu M, O'Reilly EM, Duffy A, Gansukh B, Saltz LL, Abou-Alfa GK: Advanced hepatocellular carcinoma: which staging systems best predict prognosis? J Clin Oncol; 2010 Jun 10;28(17):2889-95
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced hepatocellular carcinoma: which staging systems best predict prognosis?
  • The outcome of advanced hepatocellular carcinoma (HCC) depends on both the cancer stage and the extent of liver dysfunction.
  • PATIENTS AND METHODS: Patients with advanced HCC treated over a 5-year period at Memorial Sloan-Kettering Cancer Center were identified from an electronic medical record database.
  • CONCLUSION: In our selected patient population, CLIP, CUPI, and GETCH were the most informative staging systems in predicting survival in patients with advanced HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2008 Jun;19(6):1117-26 [18303031.001]
  • [Cites] J Natl Cancer Inst. 2008 May 21;100(10):698-711 [18477802.001]
  • [Cites] J Natl Compr Canc Netw. 2009 Apr;7(4):397-403 [19406040.001]
  • [Cites] Hepatology. 2000 Apr;31(4):840-5 [10733537.001]
  • [Cites] J Hepatol. 2001 Sep;35(3):421-30 [11592607.001]
  • [Cites] Cancer. 2002 Mar 15;94(6):1760-9 [11920539.001]
  • [Cites] Arch Intern Med. 2003 Jan 27;163(2):218-24 [12546613.001]
  • [Cites] J Gastroenterol. 2003;38(3):207-15 [12673442.001]
  • [Cites] J Am Coll Surg. 2003 Nov;197(5):753-8 [14585409.001]
  • [Cites] J Hepatol. 2004 Jan;40(1):124-31 [14672623.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):918-28 [2990661.001]
  • [Cites] Eur J Cancer. 1996 Jun;32A(7):1135-41 [8758243.001]
  • [Cites] Hepatology. 1998 Sep;28(3):751-5 [9731568.001]
  • [Cites] Dig Dis Sci. 1999 Jun;44(6):1249-53 [10389705.001]
  • [Cites] J Hepatol. 1999 Jul;31(1):133-41 [10424293.001]
  • [Cites] Semin Liver Dis. 1999;19(3):329-38 [10518312.001]
  • [Cites] Hepatology. 2004 Dec;40(6):1396-405 [15565571.001]
  • [Cites] Gut. 2005 Mar;54(3):411-8 [15710992.001]
  • [Cites] Hepatology. 2005 Apr;41(4):707-16 [15795889.001]
  • [Cites] J Hepatol. 2006 Apr;44(4):723-31 [16488051.001]
  • [Cites] Cancer. 2006 May 15;106(10):2181-9 [16596622.001]
  • [Cites] J Am Coll Surg. 2006 Oct;203(4):426-35 [17000385.001]
  • [Cites] Semin Oncol. 2006 Dec;33(6 Suppl 11):S79-83 [17178294.001]
  • [Cites] Hepatogastroenterology. 2007 Jul-Aug;54(77):1534-8 [17708292.001]
  • [Cites] Am J Gastroenterol. 2008 Mar;103(3):597-604 [17970836.001]
  • [CommentIn] J Hepatol. 2012 Feb;56(2):488-9 [21798220.001]
  • (PMID = 20458042.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3651603
  •  go-up   go-down


9. Furuse J, Ishii H, Nagase M, Kawashima M, Ogino T, Yoshino M: Adverse hepatic events caused by radiotherapy for advanced hepatocellular carcinoma. J Gastroenterol Hepatol; 2005 Oct;20(10):1512-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adverse hepatic events caused by radiotherapy for advanced hepatocellular carcinoma.
  • BACKGROUND: Radiotherapy is often used to treat patients with unresectable advanced hepatocellular carcinoma (HCC).
  • CONCLUSIONS: Hypoalbuminemia, hyperbilirubinemia, and ascites were important hepatic adverse events that developed after applying radiotherapy to treat advanced HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / radiotherapy. Liver / radiation effects. Liver Neoplasms / radiotherapy. Radiation Injuries / epidemiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Ascites / etiology. Female. Humans. Hyperbilirubinemia / etiology. Hypoalbuminemia / etiology. Male. Middle Aged. Prognosis. Radiotherapy / adverse effects. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16174067.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


10. Aramaki M, Kawano K, Sasaki A, Ohno T, Tahara K, Kai S, Iwashita Y, Kitano S: Hepatocellular carcinoma in young adults. Hepatogastroenterology; 2005 Nov-Dec;52(66):1795-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma in young adults.
  • BACKGROUND/AIMS: Hepatocellular carcinoma (HCC) is uncommon in adolescent and young adult Japanese.
  • Eight patients (72.7%) had abdominal pain directly caused by advanced tumors.
  • Most patients had highly advanced HCC; 9 patients (81.8%) had tumors larger than 10cm in diameter, and all had portal invasion.
  • [MeSH-major] Carcinoma, Hepatocellular / epidemiology. Carcinoma, Hepatocellular / pathology. Liver Neoplasms / epidemiology. Liver Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Cross-Sectional Studies. Female. Hepatectomy / methods. Humans. Incidence. Japan / epidemiology. Liver Function Tests. Male. Neoplasm Staging. Prognosis. Risk Assessment. Sex Distribution. Survival Analysis. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16334779.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


11. Fernández-Ruiz M, Guerra-Vales JM, Llenas-García J, Colina-Ruizdelgado F: [Hepatocellular carcinoma in the elderly: clinical characteristics, survival analysis, and prognostic indicators in a cohort of Spanish patients older than 75 years]. Rev Esp Enferm Dig; 2008 Oct;100(10):625-31
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hepatocellular carcinoma in the elderly: clinical characteristics, survival analysis, and prognostic indicators in a cohort of Spanish patients older than 75 years].
  • [Transliterated title] Carcinoma hepatocelular en el anciano: características clínicas, análisis de supervivencia y factores pronósticos en una cohorte de pacientes españoles mayores de 75 años.
  • AIMS: Hepatocellular carcinoma (HCC) remains poorly characterized in elderly patients with comorbid conditions, a fact that limits the clinical management of the disease.
  • Patients of advanced age were more frequently diagnosed in the presence of clinical manifestations, and had multifocal, non-localized disease and alpha-fetoprotein levels > 400 ng/mL (all p < 0.05).
  • Advanced age continued to be a prognostic factor of poor survival in the multivariate analysis (p = 0.025), but lost significance when the analysis was stratified by treatment subgroups (p = 0.344).
  • [MeSH-major] Carcinoma, Hepatocellular / mortality. Carcinoma, Hepatocellular / therapy. Liver Neoplasms / mortality. Liver Neoplasms / therapy. Survival Analysis
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Chi-Square Distribution. Female. Humans. Logistic Models. Male. Middle Aged. Multivariate Analysis. Prognosis. Proportional Hazards Models. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19119788.001).
  • [ISSN] 1130-0108
  • [Journal-full-title] Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva
  • [ISO-abbreviation] Rev Esp Enferm Dig
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


12. Bustíos Sánchez C, Díaz Ferrer J, Román Vargas R, Dávalos Moscol M, Zumaeta Villena E: [Clinical - Epidemiological characteristics of the Hepatocellular Carcinoma and treatment in the departament of digestive system diseases of the National Hospital "Eduardo Rebagliatti Martins" (HNERM) - ESSALUD]. Rev Gastroenterol Peru; 2009 Jan-Mar;29(1):17-23
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical - Epidemiological characteristics of the Hepatocellular Carcinoma and treatment in the departament of digestive system diseases of the National Hospital "Eduardo Rebagliatti Martins" (HNERM) - ESSALUD].
  • [Transliterated title] Características clínico - epidemiológicas del Carcinoma Hepatocelular y su tratamiento en el departamento del aparato digestivo del HNERM ES-SALUD.
  • Hepatocellular carcinoma (CHC) is one of the leading causes of worldwide cancer mortality.
  • High percentage of patients is diagnosed with an advanced stage of HCC.
  • [MeSH-major] Carcinoma, Hepatocellular. Liver Neoplasms
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Hospital Departments. Hospitals. Humans. Male. Middle Aged. Peru. Prospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19424404.001).
  • [ISSN] 1022-5129
  • [Journal-full-title] Revista de gastroenterología del Perú : órgano oficial de la Sociedad de Gastroenterología del Perú
  • [ISO-abbreviation] Rev Gastroenterol Peru
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Peru
  •  go-up   go-down


13. Sangro B, Bilbao JI, Boan J, Martinez-Cuesta A, Benito A, Rodriguez J, Panizo A, Gil B, Inarrairaegui M, Herrero I, Quiroga J, Prieto J: Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys; 2006 Nov 1;66(3):792-800
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma.
  • PURPOSE: To investigate the antitumor effect of resin microspheres loaded with 90-yttrium against hepatocellular carcinoma and their safety in the setting of liver cirrhosis.
  • PATIENTS AND METHODS: Data from 24 consecutive patients with hepatocellular carcinoma (HCC) treated by radioembolization in the period from September 2003 to February 2005 were reviewed.
  • [MeSH-major] Carcinoma, Hepatocellular / radiotherapy. Embolization, Therapeutic / methods. Liver Neoplasms / radiotherapy. Microspheres. Radiopharmaceuticals / administration & dosage. Yttrium Radioisotopes / administration & dosage
  • [MeSH-minor] Adult. Aged. Female. Humans. Liver / radiation effects. Male. Middle Aged. Radiotherapy Dosage. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16904840.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0 / Yttrium Radioisotopes
  •  go-up   go-down


14. Lai EC, Tang CN, Ha JP, Tsui DK, Li MK: Cytoreductive surgery in multidisciplinary treatment of advanced hepatocellular carcinoma. ANZ J Surg; 2008 Jun;78(6):504-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive surgery in multidisciplinary treatment of advanced hepatocellular carcinoma.
  • BACKGROUND: Cytoreductive surgery (debulking surgery) as a multidisciplinary treatment approach for inoperable advanced hepatocellular carcinoma has been shown to prolong survival and provide symptomatic relief for good surgical risks patients in non-randomized studies before.
  • The outcome of a consecutive series of patients with inoperable advanced hepatocellular carcinoma who received cytoreductive surgery was compared with a control group of patients who received palliative treatment without surgery.
  • CONCLUSION: Cytoreductive treatment strategy for advanced hepatocellular carcinoma can be considered as one of the options in selected patients with low operative risks and reasonable liver function.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatectomy / mortality. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Catheter Ablation. Chemoembolization, Therapeutic. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18522575.001).
  • [ISSN] 1445-2197
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


15. Li S, Niu Z, Tian H, Zhang B, Wang F, Yi LH, Yu J: Treatment of advanced hepatocellular carcinoma with gemcitabine plus oxaliplatin. Hepatogastroenterology; 2007 Jan-Feb;54(73):218-23
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of advanced hepatocellular carcinoma with gemcitabine plus oxaliplatin.
  • BACKGROUND/AIMS: To investigate the effects of gemcitabine-oxaliplatin in patients with advanced unresectable hepatocellular carcinoma (HCC).
  • In view of these treatment results, gemcitabine-oxaliplatin combination therapy with this particular dose regimen should not be considered in patients with advanced hepatocellular carcinoma.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Deoxycytidine / analogs & derivatives. Liver Neoplasms / drug therapy. Organoplatinum Compounds / administration & dosage
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Humans. Infusions, Intravenous. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17419264.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


16. Hsu WC, Chan SC, Ting LL, Chung NN, Wang PM, Ying KS, Shin JS, Chao CJ, Lin GD: Results of three-dimensional conformal radiotherapy and thalidomide for advanced hepatocellular carcinoma. Jpn J Clin Oncol; 2006 Feb;36(2):93-9
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of three-dimensional conformal radiotherapy and thalidomide for advanced hepatocellular carcinoma.
  • PURPOSE: To evaluate the effectiveness of three-dimensional conformal radiotherapy and thalidomide in the treatment of advanced hepatocellular carcinoma.
  • METHODS: Between 1999 and 2003, 121 patients (mean age, 54.4 +/- 12.4 years; range, 20-81 years) with advanced hepatocellular carcinoma received three-dimensional conformal radiotherapy and thalidomide.
  • CONCLUSIONS: Three-dimensional conformal radiotherapy with thalidomide seems to be effective in the treatment of advanced hepatocellular carcinoma.
  • [MeSH-major] Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / radiotherapy. Combined Modality Therapy. Liver Neoplasms / drug therapy. Liver Neoplasms / radiotherapy. Radiotherapy, Conformal. Thalidomide / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Female. Humans. Imaging, Three-Dimensional. Male. Middle Aged. Prognosis. Survival Analysis. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16517834.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


17. Zuckermann M, Batignani G, Leo F, Tonelli F: [Surgical treatment of hepatocellular carcinoma: prognostic factors for long-term disease-free survival and tumor recurrence]. Suppl Tumori; 2005 May-Jun;4(3):S51-2
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of hepatocellular carcinoma: prognostic factors for long-term disease-free survival and tumor recurrence].
  • [Transliterated title] La terapia chirurgica del carcinoma epatocellulare: fattori prognostici per la sopravvivenza a lungo termine libera da malattia e la recidiva tumorale.
  • Hepatocellular carcinoma mainly develops in a cirrhotic liver; in the majority of the patients chronic hepatitis or cirrhosis are virus-related and/or postalcoholic.
  • Liver resection is the gold standard treatment when there is no multifocality of the tumor and liver disease is not advanced (patients with Child-Pugh A score, or B in selected cases).
  • [MeSH-major] Carcinoma, Hepatocellular / mortality. Carcinoma, Hepatocellular / surgery. Liver Neoplasms / mortality. Liver Neoplasms / surgery. Neoplasm Recurrence, Local / epidemiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437898.001).
  • [ISSN] 2283-5423
  • [Journal-full-title] I supplementi di Tumori : official journal of Società italiana di cancerologia ... [et al.]
  • [ISO-abbreviation] Suppl Tumori
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


18. Hosaka T, Ikeda K, Kobayashi M, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Saitoh S, Arase Y, Kumada H: Predictive factors of advanced recurrence after curative resection of small hepatocellular carcinoma. Liver Int; 2009 May;29(5):736-42
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive factors of advanced recurrence after curative resection of small hepatocellular carcinoma.
  • BACKGROUND: The tumour recurrence rate after resection is still high even in patients with small hepatocellular carcinoma (HCC).
  • The advanced patterns of recurrence occasionally occur after resection.
  • In this study, we analysed the clinical and histological characteristics of small HCC and evaluated the predictive factors of advanced tumour recurrence.
  • Patterns of tumour recurrences were classified into advanced recurrence and minor recurrence based on size, number, vascular invasion and extrahepatic metastasis of recurrent tumour.
  • Tumour multiplicity, ASRI and tumour differentiation were independent and significant predictive factors of advanced recurrences.
  • The overall survival rates were lower in the advanced recurrence group than the minor recurrence or the no recurrence group.
  • CONCLUSIONS: Patients with advanced recurrences have a poor prognosis, although they have undergone curative resection of small HCC.
  • ASRI was a useful index to predict advanced recurrence after curative resection of small HCC.
  • The therapeutic management to prevent advanced recurrences is needed.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Neoplasms / surgery. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Multivariate Analysis. Predictive Value of Tests. Risk Factors. Survival Analysis. alpha-Fetoproteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19018978.001).
  • [ISSN] 1478-3231
  • [Journal-full-title] Liver international : official journal of the International Association for the Study of the Liver
  • [ISO-abbreviation] Liver Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


19. Xu L, Li P, Lin XJ, Yuan YF, Zhang YQ, Chen MS: [Clinical observation of sorafenib monotherapy in Chinese patients with advanced hepatocellular carcinoma]. Zhonghua Zhong Liu Za Zhi; 2009 Jan;31(1):58-61
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical observation of sorafenib monotherapy in Chinese patients with advanced hepatocellular carcinoma].
  • OBJECTIVE: To observe the efficacy and safety of sorafenib monotherapy in Chinese patients with advanced hepatocellular carcinoma (HCC).
  • METHODS: Thirty-eight patients with advanced HCC of Child-Pugh status A or B were included in this study.
  • CONCLUSION: Sorafenib monotherapy is effective and tolerable in a part of Chinese patients with advanced hepatocellular carcinoma and liver function of Child-Pugh A or B, and may prolong their survival.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Pyridines / therapeutic use
  • [MeSH-minor] Adult. Aged. Diarrhea / chemically induced. Female. Foot Dermatoses / chemically induced. Hand Dermatoses / chemically induced. Humans. Male. Middle Aged. Neoplasm Staging. Niacinamide / analogs & derivatives. Phenylurea Compounds. Protein Kinase Inhibitors / adverse effects. Protein Kinase Inhibitors / therapeutic use. Remission Induction. Survival Rate. Syndrome. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19538872.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


20. Hebbar M, Ernst O, Cattan S, Dominguez S, Oprea C, Mathurin P, Triboulet JP, Paris JC, Pruvot FR: Phase II trial of docetaxel therapy in patients with advanced hepatocellular carcinoma. Oncology; 2006;70(2):154-8
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of docetaxel therapy in patients with advanced hepatocellular carcinoma.
  • OBJECTIVES: We assessed the safety and efficacy of docetaxel, a microtubule inhibitor, in patients with advanced hepatocellular carcinoma (HCC).
  • CONCLUSION: When used in this schedule, docetaxel does not appear to be safe and effective enough in patients with advanced HCC and cirrhosis.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Taxoids / therapeutic use
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Drug Administration Schedule. Female. Humans. Liver Cirrhosis / complications. Male. Middle Aged. Survival Analysis. Treatment Failure

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16645329.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel
  •  go-up   go-down


21. Ueshima K, Kudo M, Takita M, Nagai T, Tatsumi C, Ueda T, Kitai S, Ishikawa E, Yada N, Inoue T, Hagiwara S, Minami Y, Chung H: Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma. Oncology; 2010 Jul;78 Suppl 1:148-53
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma.
  • BACKGROUND: Although hepatic arterial infusion chemotherapy (HAIC) using low-dose 5-fluorouracil (5-FU) and cisplatin (low-dose FP) is commonly used for advanced hepatocellular carcinoma (HCC) with vascular invasion in Japan, few reports have investigated the efficacy and safety of this approach.
  • We investigated the efficacy and toxicity of HAIC using low-dose FP for patients with advanced HCC as a phase II trial.
  • CONCLUSIONS: HAIC using low-dose FP is an effective treatment option for locally advanced HCC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Hepatocellular / drug therapy. Hepatic Artery / drug effects. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Infusions, Intra-Arterial. Male. Maximum Tolerated Dose. Middle Aged. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 S. Karger AG, Basel.
  • (PMID = 20616598.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


22. Lin JC, Shih YL, Chien PJ, Liu CL, Lee JJ, Liu TP, Ko WC, Shih CM: Increased percentage of B cells in patients with more advanced hepatocellular carcinoma. Hum Immunol; 2010 Jan;71(1):58-62
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased percentage of B cells in patients with more advanced hepatocellular carcinoma.
  • To compare immunologic phenotypes between (1) hepatocellular carcinoma (HCC) patients and a healthy population and (2) more advanced and early stage HCC patients, we studied 45 HCC patients and 46 healthy controls from January 2006 to January 2008.
  • Most importantly, a higher percentage of B cells was found in patients with advanced HCC than in those with early HCC in terms of TNM stage (II and III vs I, p = 0.004), the Japanese Integrated Scoring system (2-3 vs 0-1, p = 0.0235), and tumor numbers (> or =2 vs 1, p = 0.005).
  • A higher percentage of B cells was found in patients with more advanced HCC compared with patients with early stage HCC, which might serve as an indicator of the severity of HCC.
  • [MeSH-major] B-Lymphocytes / immunology. Carcinoma, Hepatocellular / immunology. Carcinoma, Hepatocellular / pathology. Liver Neoplasms / immunology
  • [MeSH-minor] Adult. Aged. Cell Proliferation. Disease Progression. Female. Humans. Killer Cells, Natural / immunology. Leukocytes / immunology. Leukocytes / pathology. Male. Middle Aged. Neoplasm Staging. Phagocytosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19819282.001).
  • [ISSN] 1879-1166
  • [Journal-full-title] Human immunology
  • [ISO-abbreviation] Hum. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


23. Wörns MA, Schuchmann M, Düber C, Otto G, Galle PR, Weinmann A: Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment. Oncology; 2010;79(1-2):85-92
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment.
  • OBJECTIVE: To evaluate the safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma (HCC) after progression under sorafenib treatment.
  • CONCLUSIONS: Sunitinib provided modest antitumor activity in patients with advanced HCC after progression under sorafenib treatment.
  • Hemorrhagic complications may represent a clinically relevant problem of sunitinib in patients with advanced HCC.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Indoles / therapeutic use. Liver Neoplasms / drug therapy. Pyridines / therapeutic use. Pyrroles / therapeutic use
  • [MeSH-minor] Adult. Aged. Disease Progression. Drug Administration Schedule. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. Niacinamide / analogs & derivatives. Phenylurea Compounds. Retrospective Studies. Severity of Illness Index. Treatment Failure. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • (PMID = 21071995.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Indoles; 0 / Phenylurea Compounds; 0 / Pyridines; 0 / Pyrroles; 0 / sunitinib; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


24. Nagai H, Miyaki D, Matsui T, Kanayama M, Higami K, Momiyama K, Ikehara T, Watanabe M, Sumino Y, Miki K: Changes of cytokines in cirrhosis patients with advanced hepatocellular carcinoma treated by intra-arterial chemotherapy. Cancer Chemother Pharmacol; 2008 Jul;62(2):271-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes of cytokines in cirrhosis patients with advanced hepatocellular carcinoma treated by intra-arterial chemotherapy.
  • The aim of this study was to clarify changes of cytokines in patients with liver cirrhosis (LC) and advanced hepatocellular carcinoma (aHCC) receiving intra-arterial combination chemotherapy.
  • METHODS: Twenty-one adult Japanese LC patients with aHCC received intra-arterial combination chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Carcinoma, Hepatocellular. Cytokines / blood. Liver Cirrhosis. Liver Neoplasms

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17899083.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cytokines; 0 / Fas Ligand Protein; 0 / TNF Receptor-Associated Factor 1; 0 / Tumor Necrosis Factor-alpha; EC 2.6.1.- / Transaminases
  •  go-up   go-down


25. Chia WK, Ong S, Toh HC, Hee SW, Choo SP, Poon DY, Tay MH, Tan CK, Koo WH, Foo KF: Phase II trial of gemcitabine in combination with cisplatin in inoperable or advanced hepatocellular carcinoma. Ann Acad Med Singapore; 2008 Jul;37(7):554-8
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of gemcitabine in combination with cisplatin in inoperable or advanced hepatocellular carcinoma.
  • INTRODUCTION: Advanced hepatocellular carcinoma (HCC) has a dismal prognosis and is notoriously chemo-resistant.
  • We conducted a Phase II prospective study to evaluate the activity and tolerability of gemcitabine and cisplatin in chemo-naïve advanced hepatocellular carcinoma.
  • MATERIALS AND METHODS: Patients with advanced HCC, diagnosed based on histology or by World Health Organization (WHO) criteria, were administered gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 on day 1 and day 8 of a 21-day schedule.
  • Based on the results of our phase 2 study, we are unable to recommend further studies utilising gemcitabine and cisplatin combination in patients with advanced HCC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adult. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prospective Studies. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18695766.001).
  • [ISSN] 0304-4602
  • [Journal-full-title] Annals of the Academy of Medicine, Singapore
  • [ISO-abbreviation] Ann. Acad. Med. Singap.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


26. Sarin SK, Kumar M, Garg S, Hissar S, Pandey C, Sharma BC: High dose vitamin K3 infusion in advanced hepatocellular carcinoma. J Gastroenterol Hepatol; 2006 Sep;21(9):1478-82
Hazardous Substances Data Bank. MENADIONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High dose vitamin K3 infusion in advanced hepatocellular carcinoma.
  • BACKGROUND AND AIM: The survival of patients with unresectable advanced hepatocellular carcinoma (HCC) with portal vein thrombosis is dismal.
  • Vitamin K has been shown to have antitumor effect on HCC cells both in cell lines and patients with advanced HCC.
  • The aim of this study was to assess the clinical efficacy of high dose vitamin K3 in the treatment of advanced HCC with portal vein thrombosis.
  • METHODS: Forty-two consecutive patients with advanced HCC (Stage C according to BCLC staging system) with portal vein thrombosis were randomized into two groups: (i) high dose vitamin K3 (n = 23); and (ii) placebo (n = 19).
  • [MeSH-major] Antifibrinolytic Agents / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Vitamin K 3 / therapeutic use
  • [MeSH-minor] Adult. Humans. Kaplan-Meier Estimate. Middle Aged. Neoplasm Staging. Placebos. Portal Vein / pathology. Survival Rate. Treatment Outcome. Venous Thrombosis / drug therapy. Venous Thrombosis / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16911696.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antifibrinolytic Agents; 0 / Placebos; 723JX6CXY5 / Vitamin K 3
  •  go-up   go-down


27. Kim SJ, Han SW, Oh DY, Yi NJ, Kim YJ, Im SA, Yoon JH, Kang GH, Suh KS, Bang YJ, Jang JJ, Kim TY: Combination chemotherapy with S-1 and platinum in advanced hepatocellular carcinoma. Anticancer Res; 2010 Dec;30(12):5245-50
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination chemotherapy with S-1 and platinum in advanced hepatocellular carcinoma.
  • BACKGROUND: Based on its potent inhibition of dihydropyrimidine dehydrogenase (DPD), S-1 is expected to be more active than other flouropyrimidines against tumors with higher DPD activity, such as hepatocellular carcinoma (HCC).
  • CONCLUSION: S-1 and platinum combination chemotherapy shows favorable efficacy and tolerability in advanced HCC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / biosynthesis. Cisplatin / administration & dosage. Cisplatin / adverse effects. Drug Combinations. Female. Humans. Immunohistochemistry. Male. Middle Aged. Organoplatinum Compounds / administration & dosage. Organoplatinum Compounds / adverse effects. Oxonic Acid / administration & dosage. Oxonic Acid / adverse effects. Retrospective Studies. Tegafur / administration & dosage. Tegafur / adverse effects

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • GeneTex Inc. NCBI Redirect Page | Genetex Inc. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21187521.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Drug Combinations; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


28. Ang MK, Poon D, Foo KF, Chung YF, Chow P, Wan WK, Thng CH, Ooi L: A new chemoimmunotherapy regimen (OXAFI) for advanced hepatocellular carcinoma. Hematol Oncol Stem Cell Ther; 2008 Jul-Sep;1(3):159-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A new chemoimmunotherapy regimen (OXAFI) for advanced hepatocellular carcinoma.
  • BACKGROUND: Chemotherapeutic treatment options for advanced unresectable and/or metastatic hepatocellular carcinoma (HCC) are limited.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adult. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Humans. Interferon-alpha / administration & dosage. Interferon-alpha / adverse effects. Male. Middle Aged. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Organoplatinum Compounds / adverse effects. Recombinant Proteins

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20063546.001).
  • [ISSN] 1658-3876
  • [Journal-full-title] Hematology/oncology and stem cell therapy
  • [ISO-abbreviation] Hematol Oncol Stem Cell Ther
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Organoplatinum Compounds; 0 / Recombinant Proteins; 04ZR38536J / oxaliplatin; 80168379AG / Doxorubicin; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


29. Xu LT, Chen Z, Lin JH, Zhou ZH, Chen H, Meng ZQ, Liu LM: [Clinical observation of transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma]. Zhonghua Zhong Liu Za Zhi; 2010 Sep;32(9):703-5
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical observation of transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma].
  • OBJECTIVE: To observe the efficacy and side effects of transarterial chemoembolization (TACE) combined with sorafenib for advanced hepatocellular carcinoma (HCC).
  • CONCLUSION: The combined therapy of TACE and sorafenib is effective and well tolerated for advanced HCC.
  • [MeSH-major] Benzenesulfonates / therapeutic use. Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic. Liver Neoplasms / therapy. Pyridines / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Diarrhea / etiology. Disease Progression. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Doxorubicin / analogs & derivatives. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Niacinamide / analogs & derivatives. Organoplatinum Compounds / administration & dosage. Organoplatinum Compounds / adverse effects. Phenylurea Compounds. Remission Induction. Survival Rate. Thrombocytopenia / etiology. Young Adult

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21122388.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Organoplatinum Compounds; 0 / Phenylurea Compounds; 0 / Pyridines; 04ZR38536J / oxaliplatin; 25X51I8RD4 / Niacinamide; 80168379AG / Doxorubicin; 9ZOQ3TZI87 / sorafenib; D58G680W0G / pirarubicin
  •  go-up   go-down


30. Yamasaki T, Kimura T, Kurokawa F, Aoyama K, Ishikawa T, Tajima K, Yokoyama Y, Takami T, Omori K, Kawaguchi K, Tsuchiya M, Terai S, Sakaida I, Okita K: Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy. J Gastroenterol; 2005 Jan;40(1):70-8
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy.
  • BACKGROUND: The prognosis of patients with advanced hepatocellular carcinoma (HCC) is poor.
  • We aimed to clarify the prognostic factors in patients with advanced HCC receiving hepatic arterial infusion chemotherapy (HAIC).
  • CONCLUSIONS: Patients who had advanced HCC with favorable hepatic reserve capacity and a lower AFP level were suitable candidates for HAIC.
  • Moreover, the regimen using low-dose CDDP and 5-FU with leucovorin/isovorin may be suitable for advanced HCC patients, because of the improvement in the response rate and survival compared with the low-dose CDDP and 5-FU regimen without leucovorin/isovorin.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Carcinoma, Hepatocellular / diagnosis. Carcinoma, Hepatocellular / drug therapy. Hepatic Artery / chemistry. Hepatic Artery / drug effects. Liver Neoplasms / diagnosis. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / administration & dosage. Cause of Death. Cisplatin / administration & dosage. Dose-Response Relationship, Drug. Female. Fluorouracil / administration & dosage. Humans. Infusions, Intra-Arterial. Japan / epidemiology. Leucovorin / administration & dosage. Male. Middle Aged. Multivariate Analysis. Prognosis. Survival Analysis. Time Factors. Treatment Outcome. Vitamin B Complex / administration & dosage

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15692792.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 12001-76-2 / Vitamin B Complex; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


31. Jang JW, Kay CS, You CR, Kim CW, Bae SH, Choi JY, Yoon SK, Han CW, Jung HS, Choi IB: Simultaneous multitarget irradiation using helical tomotherapy for advanced hepatocellular carcinoma with multiple extrahepatic metastases. Int J Radiat Oncol Biol Phys; 2009 Jun 1;74(2):412-8
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous multitarget irradiation using helical tomotherapy for advanced hepatocellular carcinoma with multiple extrahepatic metastases.
  • PURPOSE: The prognosis of hepatocellular carcinoma (HCC) patients with extrahepatic metastases is extremely poor.
  • This study evaluated the feasibility and outcome of tomotherapy for advanced HCC with metastases.
  • CONCLUSION: The results of this study have shown that helical tomotherapy is safe and feasible without major toxicities for the treatment of advanced HCC and results in excellent tumor control and a potential survival benefit.
  • [MeSH-major] Carcinoma, Hepatocellular / radiotherapy. Liver Neoplasms / radiotherapy. Radiotherapy, Intensity-Modulated / methods
  • [MeSH-minor] Adrenal Gland Neoplasms / secondary. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemoembolization, Therapeutic / methods. Cisplatin / administration & dosage. Combined Modality Therapy / methods. Epirubicin / administration & dosage. Feasibility Studies. Female. Humans. Iodized Oil / administration & dosage. Lung Neoplasms / secondary. Lymphatic Metastasis / radiotherapy. Male. Middle Aged. Radiotherapy Dosage. Survival Rate

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18963538.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 8001-40-9 / Iodized Oil; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


32. Uka K, Aikata H, Takaki S, Kawaoka T, Saneto H, Miki D, Takahashi S, Toyota N, Ito K, Chayama K: Systemic gemcitabine combined with intra-arterial low-dose cisplatin and 5-fluorouracil for advanced hepatocellular carcinoma: seven cases. World J Gastroenterol; 2008 Apr 28;14(16):2602-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic gemcitabine combined with intra-arterial low-dose cisplatin and 5-fluorouracil for advanced hepatocellular carcinoma: seven cases.
  • The combination of intra-arterial low-dose cisplatin and 5-fluorouracil (5-FU) is effective against advanced hepatocellular carcinoma (HCC).
  • Seven patients with non-resectable advanced HCC were treated with GEMFP.
  • GEMFP may potentially be effective for non-resectable advanced HCC, but it has severe hematologic toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Patient Selection. Survival Analysis. Survivors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Cancer. 2007 Jul 1;110(1):129-37 [17508408.001]
  • [Cites] Liver Int. 2007 Nov;27(9):1209-16 [17919232.001]
  • [Cites] J Gastroenterol. 2007 Oct;42(10):845-53 [17940838.001]
  • [Cites] Cancer. 2002 Jan 15;94(2):435-42 [11900229.001]
  • [Cites] Cancer. 2002 Aug 1;95(3):588-95 [12209752.001]
  • [Cites] Am J Surg. 2002 Sep;184(3):284-90 [12354601.001]
  • [Cites] World J Gastroenterol. 2003 Dec;9(12):2666-70 [14669309.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1983 Dec;9(12):1841-50 [6319339.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Dec;83(23):8923-5 [3466165.001]
  • [Cites] Cancer Res. 1987 Sep 15;47(18):4967-72 [3040235.001]
  • [Cites] Cancer. 1988 May 15;61(10):1983-7 [2834036.001]
  • [Cites] Ann Surg. 1988 Jul;208(1):23-35 [2839123.001]
  • [Cites] Am J Clin Oncol. 1989 Oct;12(5):397-401 [2801599.001]
  • [Cites] Eur J Surg Oncol. 1992 Apr;18(2):156-61 [1316289.001]
  • [Cites] Br J Cancer. 1993 Jul;68(1):52-6 [8318420.001]
  • [Cites] Cancer. 1997 May 15;79(10):1890-6 [9149014.001]
  • [Cites] Cancer. 1997 Jun 1;79(11):2087-94 [9179054.001]
  • [Cites] Hepatology. 1998 Sep;28(3):751-5 [9731568.001]
  • [Cites] Hepatology. 1999 Jan;29(1):62-7 [9862851.001]
  • [Cites] Br J Cancer. 2005 Sep 5;93(5):557-64 [16106266.001]
  • [Cites] Trop Gastroenterol. 2005 Jul-Sep;26(3):115-8 [16512457.001]
  • [Cites] J Med Virol. 2006 Apr;78(4):459-65 [16482557.001]
  • [Cites] Cancer. 2006 May 1;106(9):1990-7 [16565970.001]
  • [Cites] World J Gastroenterol. 2007 Jan 21;13(3):414-20 [17230611.001]
  • [Cites] Cancer. 2007 Apr 1;109(7):1384-90 [17330837.001]
  • [Cites] Cancer. 2000 Aug 15;89(4):750-6 [10951336.001]
  • (PMID = 18442216.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2708380
  •  go-up   go-down


33. Obed A, Tsui TY, Schnitzbauer AA, Obed M, Schlitt HJ, Becker H, Lorf T: Liver transplantation as curative approach for advanced hepatocellular carcinoma: is it justified? Langenbecks Arch Surg; 2008 Mar;393(2):141-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation as curative approach for advanced hepatocellular carcinoma: is it justified?
  • BACKGROUND: Liver transplantation is considered as one of therapeutic approaches to hepatocellular carcinoma (HCC).
  • There were no significant differences in 1- and 5-year survivals of patients with early tumour stage received LTx or primary tumour resection, whereas patients in advanced tumour stage based on pathological findings of explanted liver significantly benefited from LTx as compared to primary resection.
  • CONCLUSIONS: LTx can be a curative approach for patients with advanced HCC without extrahepatic metastasis.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatology. 1999 Dec;30(6):1434-40 [10573522.001]
  • [Cites] Liver Transpl. 2006 Aug;12(8):1260-7 [16826556.001]
  • [Cites] Hepatology. 2001 May;33(5):1080-6 [11343235.001]
  • [Cites] J Hepatol. 2001 Sep;35(3):421-30 [11592607.001]
  • [Cites] Liver Transpl. 2001 Oct;7(10):877-83 [11679986.001]
  • [Cites] Semin Oncol. 2001 Oct;28(5):474-86 [11685740.001]
  • [Cites] Ann Surg. 2002 May;235(5):722-30; discussion 730-1 [11981219.001]
  • [Cites] Hepatology. 2002 May;35(5):1164-71 [11981766.001]
  • [Cites] Ann Surg. 2003 Oct;238(4):508-18; discussion 518-9 [14530722.001]
  • [Cites] Liver Transpl. 2004 Feb;10(2 Suppl 1):S39-45 [14762838.001]
  • [Cites] Cancer. 2004 Aug 15;101(4):796-802 [15305412.001]
  • [Cites] Ann Surg. 1993 Aug;218(2):145-51 [8393649.001]
  • [Cites] N Engl J Med. 1996 Mar 14;334(11):693-9 [8594428.001]
  • [Cites] Gan To Kagaku Ryoho. 1997 May;24 Suppl 1:9-16 [9210883.001]
  • [Cites] Hepatology. 1998 Jun;27(6):1572-7 [9620329.001]
  • [Cites] Transpl Int. 1998;11 Suppl 1:S189-92 [9664976.001]
  • [Cites] J Hepatol. 1998 Jul;29(1):129-34 [9696501.001]
  • [Cites] J Hepatol. 1998 Dec;29(6):953-9 [9875642.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):324-31 [10458250.001]
  • [Cites] Am J Transplant. 2005 Apr;5(4 Pt 1):795-804 [15760404.001]
  • [Cites] Eur J Surg Oncol. 2005 May;31(4):331-47 [15837037.001]
  • [Cites] Transplantation. 2005 Sep 27;80(1 Suppl):S113-9 [16286887.001]
  • [Cites] Jpn J Clin Oncol. 2006 Apr;36(4):212-7 [16613896.001]
  • [Cites] Transplant Proc. 2006 May;38(4):1111-3 [16757280.001]
  • [Cites] Hepatology. 2000 Dec;32(6):1224-9 [11093728.001]
  • (PMID = 18043937.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC3085731
  •  go-up   go-down


34. Kim YJ, Lee HG, Park JM, Lim YS, Chung MH, Sung MS, Yoo WJ, Lim HW: Polyvinyl alcohol embolization adjuvant to oily chemoembolization in advanced hepatocellular carcinoma with arterioportal shunts. Korean J Radiol; 2007 Jul-Aug;8(4):311-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polyvinyl alcohol embolization adjuvant to oily chemoembolization in advanced hepatocellular carcinoma with arterioportal shunts.
  • OBJECTIVE: To assess the feasibility and safety of polyvinyl alcohol (PVA) embolization adjuvant to transarterial oily chemoembolization (P-TACE) in advanced hepatocellular carcinoma (HCC) with arterioportal shunts (APS).
  • CONCLUSION: P-TACE is feasible and safe in advanced HCC patients with APS.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic. Liver Neoplasms / therapy. Polyvinyl Alcohol / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibiotics, Antineoplastic / administration & dosage. Arteriovenous Fistula / therapy. Contrast Media / administration & dosage. Feasibility Studies. Female. Humans. Iodized Oil / administration & dosage. Liver Circulation. Male. Middle Aged. Mitomycin / administration & dosage. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. POLYVINYL ALCOHOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJNR Am J Neuroradiol. 2000 Feb;21(2):255-61 [10696005.001]
  • [Cites] AJR Am J Roentgenol. 2000 Sep;175(3):767-73 [10954464.001]
  • [Cites] Radiographics. 2002 Jan-Feb;22(1):123-40 [11796903.001]
  • [Cites] World J Gastroenterol. 2004 Mar 15;10(6):825-9 [15040025.001]
  • [Cites] Radiology. 1977 Jan;122(1):53-8 [186844.001]
  • [Cites] Radiology. 1983 Aug;148(2):397-401 [6306721.001]
  • [Cites] Radiology. 1984 Sep;152(3):621-6 [6463243.001]
  • [Cites] Cardiovasc Intervent Radiol. 1993 Nov-Dec;16(6):368-73 [8131168.001]
  • [Cites] Radiographics. 1994 May;14(3):623-43; quiz 645-6 [8066276.001]
  • [Cites] Clin Radiol. 1997 Jan;52(1):36-40 [9022578.001]
  • [Cites] Radiology. 1997 Sep;204(3):787-90 [9280260.001]
  • (PMID = 17673842.001).
  • [ISSN] 1229-6929
  • [Journal-full-title] Korean journal of radiology
  • [ISO-abbreviation] Korean J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Contrast Media; 50SG953SK6 / Mitomycin; 8001-40-9 / Iodized Oil; 9002-89-5 / Polyvinyl Alcohol
  • [Other-IDs] NLM/ PMC2627160
  •  go-up   go-down


35. Yau T, Chan P, Pang R, Ng K, Fan ST, Poon RT: Phase 1-2 trial of PTK787/ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma: implication for antiangiogenic approach to hepatocellular carcinoma. Cancer; 2010 Nov 1;116(21):5022-9
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 1-2 trial of PTK787/ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma: implication for antiangiogenic approach to hepatocellular carcinoma.
  • BACKGROUND: This phase 1-2 trial assessed the efficacy and tolerability of an oral angiogenesis inhibitor-PTK787/ZK222584 (PTK)-in combination with intravenous doxorubicin for the treatment of advanced hepatocellular carcinoma (HCC) patients.
  • METHODS: In phase 1, advanced HCC patients received PTK at escalating doses together with doxorubicin 60 mg/m2 given as an intravenous bolus every 3 weeks to establish the maximum tolerated dose (MTD).
  • CONCLUSIONS: The combination of PTK with intravenous doxorubicin shows encouraging activity in treating advanced HCC patients.
  • [MeSH-major] Angiogenesis Inhibitors / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Doxorubicin / administration & dosage. Liver Neoplasms / drug therapy. Phthalazines / administration & dosage. Pyridines / administration & dosage
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Female. Humans. Infusions, Intravenous. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Cancer Society.
  • (PMID = 20629034.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Phthalazines; 0 / Pyridines; 5DX9U76296 / vatalanib; 80168379AG / Doxorubicin
  •  go-up   go-down


36. Park JW: [Hepatocellular carcinoma in Korea: introduction and overview]. Korean J Gastroenterol; 2005 Apr;45(4):217-26
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hepatocellular carcinoma in Korea: introduction and overview].
  • Hepatocellular carcinoma (HCC) is a highly malignant, generally fatal neoplasm arising from hepatocytes.
  • Because almost eighty percent of HCC is diagnosed in late stage, we launched a nationwide surveillance program to screen high risk groups (HBV or HCV carriers or liver cirrhosis, over 40 years old) and formulated the Korean practice guideline for the diagnosis and treatment of HCC with special emphasis on advanced stage of HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / epidemiology. Liver Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Incidence. Korea / epidemiology. Male. Middle Aged. Prevalence. Risk Factors

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15843747.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


37. Romano O, Truant S, Sergent-Baudson G, Comet B, Pruvot FR, Hebbar M: Docetaxel therapy for advanced hepatocellular carcinoma developed in healthy liver: report of three cases. J Chemother; 2008 Aug;20(4):518-20
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Docetaxel therapy for advanced hepatocellular carcinoma developed in healthy liver: report of three cases.
  • Systemic chemotherapy is generally ineffective in patients with advanced hepatocellular carcinoma (HCC).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Taxoids / therapeutic use
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18676236.001).
  • [ISSN] 1973-9478
  • [Journal-full-title] Journal of chemotherapy (Florence, Italy)
  • [ISO-abbreviation] J Chemother
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Taxoids; 15H5577CQD / docetaxel
  •  go-up   go-down


38. Hashimoto E, Yatsuji S, Tobari M, Taniai M, Torii N, Tokushige K, Shiratori K: Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol; 2009;44 Suppl 19:89-95
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis.
  • BACKGROUND: There have been few reports on hepatocellular carcinoma (HCC) in nonalcoholic steatohepatitis (NASH) and the natural history of NASH.
  • Accordingly, we assessed the clinical features of HCC in NASH, the risk factors for HCC, and natural history of NASH with advanced fibrosis.
  • A prospective cohort study of the outcomes of 137 NASH with advanced fibrosis was started in 1990.
  • RESULTS: In total, 88% of patients with HCC had advanced fibrosis, with a median age of 70 years.
  • Older age, low level of AST, low grade of histological activity, and advanced stage of fibrosis were risk factors for HCC.
  • CONCLUSIONS: The present study confirmed that older age and advanced fibrosis were important risk factors for HCC, and that HCC was the major cause of mortality in NASH patients with advanced fibrosis.
  • Regular screening for HCC is thus extremely important for NASH patients with advanced fibrosis.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Fatty Liver / pathology. Liver Neoplasms / etiology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Child. Cohort Studies. Female. Humans. Liver Cirrhosis / complications. Liver Cirrhosis / pathology. Logistic Models. Male. Middle Aged. Proportional Hazards Models. Prospective Studies. Risk Factors. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19148800.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


39. Guo TK, Hao XY, Ma B, Yang KH, Li YP, Li HL, Gu YH, Cai H, Liu YL, Li Y, Zhan WP: Octreotide for advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials. J Cancer Res Clin Oncol; 2009 Dec;135(12):1685-92
PubMed Health. DARE review .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Octreotide for advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials.
  • PURPOSE: To evaluate the effectiveness of octreotide in advanced hepatocellular carcinoma participants on the basis of randomized controlled trials.
  • Randomized controlled trials of octreotide for advanced hepatocellular carcinoma were selected and evaluated by two investigators.
  • CONCLUSIONS: As for the limitations of the included trials, the result may not demonstrate a significant superiority of octreotide administration in participants with advanced hepatocellular carcinoma from the available evidence.
  • [MeSH-major] Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Octreotide / therapeutic use. Randomized Controlled Trials as Topic
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Algorithms. Antineoplastic Agents, Hormonal / therapeutic use. Disease Progression. Female. Humans. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19536563.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; RWM8CCW8GP / Octreotide
  •  go-up   go-down


40. Yuen MF, Hou JL, Chutaputti A, Asia Pacific Working Party on Prevention of Hepatocellular Carcinoma: Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol; 2009 Mar;24(3):346-53
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma in the Asia pacific region.
  • Primary liver cancer, particularly hepatocellular carcinoma (HCC) remains a significant disease worldwide.
  • The majority of patients present with advanced diseases, hence reducing the chance of curative treatment.
  • [MeSH-major] Carcinoma, Hepatocellular / epidemiology. Liver Neoplasms / epidemiology
  • [MeSH-minor] Adult. Age Factors. Asia / epidemiology. Asian Continental Ancestry Group. Female. Hepatitis B, Chronic / complications. Hepatitis B, Chronic / epidemiology. Hepatitis C, Chronic / complications. Hepatitis C, Chronic / epidemiology. Humans. Incidence. Male. Middle Aged. Odds Ratio. Prevalence. Prognosis. Risk Assessment. Risk Factors. Sex Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19220670.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Australia
  • [Number-of-references] 35
  • [Investigator] Farrell GC; Chan HL; Yuen MF; Amarapurkar DN; Chutaputti A; Fan JG; Hou JL; Han KH; Kao JH; Lim SG; Mohamed R; Sollano J; Ueno Y
  •  go-up   go-down


41. Sun J, Hou BH, Jian ZX, Ou YL, Ou JR: [Value of perioperative adjuvant therapy in liver transplantation for advanced hepatocellular carcinoma]. Nan Fang Yi Ke Da Xue Xue Bao; 2007 Apr;27(4):471-3
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Value of perioperative adjuvant therapy in liver transplantation for advanced hepatocellular carcinoma].
  • OBJECTIVE: To evaluate the clinical value of perioperative adjuvant chemotherapy in prevention of tumor recurrence and improvement of patient survival after liver transplantation for advanced hepatocellular carcinoma (HCC).
  • METHODS: Twenty patients with advanced HCC (pTNM stages III and IV a) receiving liver transplantation with preoperative transcatheter arterial chemoembolization (TACE) and postoperative adjuvant chemotherapy (ADM+5-Fu+CDDP) were retrospectively reviewed in comparison with 16 patients receiving liver transplantation only for tumor recurrence, cumulative and tumor-free survivals.
  • CONCLUSIONS: Perioperative adjuvant treatment may significantly decrease the likeliness of tumor recurrence and prolong the survival of patients with advanced HCC after liver transplantation.
  • [MeSH-major] Carcinoma, Hepatocellular / drug therapy. Chemotherapy, Adjuvant. Liver Neoplasms / drug therapy. Liver Transplantation
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Perioperative Care. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17545034.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


42. Li Y, Huang JW, Lu LG, Shao PJ, Hu BS, Huang GM, Wei ZG, Zhang L: [Clinical analysis of the treatment:transcatheter arterial chemoembolization combined with sorafenib in advanced hepatocellular carcinoma]. Zhonghua Yi Xue Za Zhi; 2010 Aug 17;90(31):2187-92
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of the treatment:transcatheter arterial chemoembolization combined with sorafenib in advanced hepatocellular carcinoma].
  • OBJECTIVE: To provide more evidence sources to the standard treatment for patients with advanced hepatocellular carcinoma, the writer analyze patients' time to progression (TTP) and overall survival (OS) after patients receiving transcatheter arterial chemoembolization (TACE) combined with sorafenib as a treatment of advanced hepatocellular carcinoma (HCC); observe the healing effect embolization combined with anti-angiogenic treatment for advanced hepatocellular carcinoma; and also analyze treatment of security.
  • CONCLUSION: Combined with sorafenib treatment may give patients with advanced hepatocellular carcinoma a longer longevity and keep the disease in a steady state.
  • This therapy can be added into the treatments to patients with advanced hepatocellular carcinoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Carcinoma, Hepatocellular / therapy. Liver Neoplasms / therapy. Pyridines / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Chemoembolization, Therapeutic. Female. Humans. Male. Middle Aged. Neoplasm Staging. Niacinamide / analogs & derivatives. Phenylurea Compounds. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21029658.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


43. Otegbayo JA, Atalabi OM, Yakubu A: Clinicoradiologic and sonographic patterns of metastasis in hepatocellular carcinoma. J Natl Med Assoc; 2006 Oct;98(10):1620-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicoradiologic and sonographic patterns of metastasis in hepatocellular carcinoma.
  • Hepatocellular carcinoma (HCC) is usually diagnosed at an advanced stage, when little remedy could be offered.
  • [MeSH-major] Carcinoma, Hepatocellular. Liver Neoplasms
  • [MeSH-minor] Adult. Cross-Sectional Studies. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis. Prospective Studies. Radiography, Thoracic

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastroenterol. 2000;35(3):240-4 [10755695.001]
  • [Cites] J Hepatol. 2001 Sep;35(3):421-30 [11592607.001]
  • [Cites] Semin Oncol. 2001 Oct;28(5):450-9 [11685738.001]
  • [Cites] Taehan Kan Hakhoe Chi. 2002 Jun;8(2):218-22 [12499808.001]
  • [Cites] Eur Radiol. 2002 Dec;12 Suppl 3:S70-3 [12522608.001]
  • [Cites] Niger Med J. 1978 Mar-Apr;8(2):108-11 [645212.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8041-7 [16258102.001]
  • [Cites] Chest. 1984 Sep;86(3):430-4 [6088178.001]
  • [Cites] Ital J Gastroenterol. 1992 Feb;24(2):95-9 [1315595.001]
  • [Cites] AJR Am J Roentgenol. 1997 Jan;168(1):280-1 [8976965.001]
  • [Cites] N Engl J Med. 1999 Mar 11;340(10):798-9 [10072416.001]
  • [Cites] Afr J Med Med Sci. 2005 Mar;34(1):51-4 [15971554.001]
  • [Cites] Int J Cancer. 2005 Nov 10;117(3):506-9 [15906357.001]
  • [Cites] J Natl Cancer Inst. 1980 May;64(5):1263-72 [6767876.001]
  • (PMID = 17052052.001).
  • [ISSN] 1943-4693
  • [Journal-full-title] Journal of the National Medical Association
  • [ISO-abbreviation] J Natl Med Assoc
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2569757
  •  go-up   go-down


44. Zhang ZH, Ma LW, Song SB, Xiu DR, Wang JJ, Yang XX, Jia YM: [Adjuvant chemotherapy after orthotopic liver transplantation for advanced hepatocellular carcinoma]. Zhonghua Zhong Liu Za Zhi; 2005 Jan;27(1):45-7
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adjuvant chemotherapy after orthotopic liver transplantation for advanced hepatocellular carcinoma].
  • OBJECTIVE: To investigate the feasibility, reliability and therapeutic effectiveness of adjuvant chemotherapy for advanced hepatocellular carcinoma (HCC) after orthotopic liver transplantation (OLT).
  • METHODS: The clinical data of adjuvant chemotherapy after OLT in 10 advanced HCC patients were studied retrospectively.
  • CONCLUSION: Chemotherapy which is able to prolong the life-span of patients with advanced HCC after orthotopic liver transplantation is feasible and effective, the side-effects were mild.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Liver Transplantation
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Leucovorin / administration & dosage. Male. Middle Aged. Neoplasm Staging. Postoperative Period. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15771799.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


45. Han KH, Seong J, Kim JK, Ahn SH, Lee DY, Chon CY: Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. Cancer; 2008 Sep 1;113(5):995-1003
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis.
  • BACKGROUND: Patients with advanced hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) have a particularly grave prognosis.
  • In the current study, an attempt was made to localize chemoradiation therapy (CCRT) followed by hepatic arterial infusion chemotherapy (HAIC) in patients with locally advanced HCC with PVT and good reserve liver function.
  • CONCLUSIONS: The substantial response rate as well as median survival time noted in the current study encourages the use of this new approach in patients with locally advanced HCC with PVT.
  • [MeSH-major] Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / radiotherapy. Liver Neoplasms / drug therapy. Liver Neoplasms / radiotherapy. Portal Vein. Venous Thrombosis / etiology
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy / adverse effects. Disease Progression. Female. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Pilot Projects


46. Yau T, Chan P, Wong H, Ng KK, Chok SH, Cheung TT, Lam V, Epstein RJ, Fan ST, Poon RT: Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma. Oncology; 2007;72 Suppl 1:67-71
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma.
  • OBJECTIVE: The systemic treatment of advanced hepatocellular carcinoma (HCC) has produced disappointing results thus far.
  • We aim to evaluate the efficacy and toxicity of low-dose (100 mg) thalidomide as the first-line treatment of advanced HCC.
  • METHODS: Between August 2003 and March 2007, 45 patients who had received thalidomide 100 mg daily as first-line treatment of advanced HCC were reviewed retrospectively.
  • Advanced HCC was defined as either metastatic or not amenable to surgical or locoregional therapies.
  • CONCLUSION: Our study shows that a single agent, low-dose thalidomide has a modest clinical activity with good tolerability in treating advanced HCC patients.
  • [MeSH-major] Angiogenesis Inhibitors / administration & dosage. Angiogenesis Inhibitors / adverse effects. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Thalidomide / administration & dosage. Thalidomide / adverse effects
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Ankle. Edema / chemically induced. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Peripheral Nervous System Diseases / chemically induced. Retrospective Studies. Sleep Stages / drug effects

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 S. Karger AG, Basel.
  • (PMID = 18087184.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


47. Ng KT, Man K, Sun CK, Lee TK, Poon RT, Lo CM, Fan ST: Clinicopathological significance of homeoprotein Six1 in hepatocellular carcinoma. Br J Cancer; 2006 Oct 23;95(8):1050-5
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological significance of homeoprotein Six1 in hepatocellular carcinoma.
  • Tumour recurrence and metastases of hepatocellular carcinoma (HCC) after hepatectomy are the major obstacles of long-term survival.
  • We concluded that Six1 is frequently overexpressed in HCC patients and elevated Six1 protein in HCC patients may be an indication of advanced stage and poor overall survival after hepatectomy.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Homeodomain Proteins / genetics. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Blotting, Western. Cell Line, Tumor. Female. Gene Expression Regulation, Neoplastic. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1999 Mar 11;340(10):745-50 [10072408.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12608-13 [9770533.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2668-75 [15805264.001]
  • [Cites] Semin Liver Dis. 2005;25(2):181-200 [15918147.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):1982-9 [16488997.001]
  • [Cites] Genes Dev. 1999 Dec 15;13(24):3171-8 [10617565.001]
  • [Cites] J Biol Chem. 2000 Jul 21;275(29):22245-54 [10801845.001]
  • [Cites] Anticancer Res. 2001 Jan-Feb;21(1B):657-62 [11299822.001]
  • [Cites] World J Gastroenterol. 2001 Oct;7(5):630-6 [11819844.001]
  • [Cites] Am J Pathol. 2002 Jun;160(6):2181-90 [12057921.001]
  • [Cites] Development. 2003 May;130(10):2239-52 [12668636.001]
  • [Cites] Development. 2003 Jul;130(14):3085-94 [12783782.001]
  • [Cites] Development. 2003 Sep;130(17):3989-4000 [12874121.001]
  • [Cites] Hepatology. 2003 Dec;38(6):1540-51 [14647065.001]
  • [Cites] Development. 2004 Feb;131(3):551-62 [14695375.001]
  • [Cites] Br J Surg. 2004 Feb;91(2):131-3 [14760656.001]
  • [Cites] Nat Med. 2004 Feb;10(2):175-81 [14704789.001]
  • [Cites] Liver Transpl. 2004 Feb;10(2 Suppl 1):S39-45 [14762838.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6478-83 [15123840.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S5-S16 [15508102.001]
  • [Cites] Development. 1995 Mar;121(3):693-705 [7720577.001]
  • [Cites] Cancer Res. 1998 Mar 1;58(5):985-90 [9500460.001]
  • [Cites] Lancet. 1999 Apr 10;353(9160):1253-7 [10217098.001]
  • (PMID = 17008870.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / RNA, Messenger; 0 / SIX1 protein, human
  • [Other-IDs] NLM/ PMC2360701
  •  go-up   go-down


48. Yang JD, Roberts LR: Epidemiology and management of hepatocellular carcinoma. Infect Dis Clin North Am; 2010 Dec;24(4):899-919, viii
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology and management of hepatocellular carcinoma.
  • Hepatocellular carcinoma (HCC) is a major world health problem because of the high incidence and case fatality rate.
  • In most patients, the diagnosis of HCC is made at an advanced stage, which limits the application of curative treatments.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • [Cites] Hepatology. 2004 Mar;39(3):804-10 [14999700.001]
  • [Cites] Cancer. 2004 Aug 15;101(4):796-802 [15305412.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1521-31 [15470215.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S194-205 [15508085.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S5-S16 [15508102.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S56-61 [15508104.001]
  • [Cites] Cancer. 1988 May 15;61(10):1942-56 [2834034.001]
  • [Cites] Cancer. 1988 Nov 1;62(9):2051-5 [2844388.001]
  • [Cites] Hepatology. 1991 Mar;13(3):398-406 [1847891.001]
  • [Cites] World J Surg. 1991 Mar-Apr;15(2):270-85 [1851588.001]
  • [Cites] N Engl J Med. 1991 Sep 5;325(10):675-80 [1651452.001]
  • [Cites] Surgery. 1991 Oct;110(4):726-34; discussion 734-5 [1656538.001]
  • [Cites] Cancer. 1992 Feb 15;69(4):925-9 [1310435.001]
  • [Cites] N Engl J Med. 1992 Aug 6;327(6):369-73 [1320736.001]
  • [Cites] Hepatology. 1992 Aug;16(2):353-7 [1322349.001]
  • [Cites] Cancer Res. 1993 Feb 15;53(4):790-4 [8381328.001]
  • [Cites] J Infect Dis. 1993 Mar;167(3):572-6 [8382718.001]
  • [Cites] N Engl J Med. 1993 Jun 24;328(25):1797-801 [7684822.001]
  • [Cites] Hepatology. 1993 Dec;18(6):1326-33 [8244256.001]
  • [Cites] N Engl J Med. 1994 Mar 17;330(11):744-50 [8107740.001]
  • [Cites] Gastroenterology. 1994 Apr;106(4):1000-5 [8143967.001]
  • [Cites] Gastroenterology. 1994 Jun;106(6):1618-24 [8194710.001]
  • [Cites] J Virol. 1995 Jun;69(6):3893-6 [7745741.001]
  • [Cites] Hepatology. 1995 Aug;22(2):432-8 [7543434.001]
  • [Cites] N Engl J Med. 1996 Mar 14;334(11):693-9 [8594428.001]
  • [Cites] Cancer. 1996 May 1;77(9):1792-6 [8646676.001]
  • [Cites] N Engl J Med. 1996 Jun 27;334(26):1685-90 [8637512.001]
  • [Cites] Gastroenterology. 1996 Oct;111(4):1018-22 [8831597.001]
  • [Cites] Abdom Imaging. 1996 Nov-Dec;21(6):488-94 [8875869.001]
  • [Cites] J Hepatol. 1996 Sep;25(3):334-8 [8895013.001]
  • [Cites] N Engl J Med. 1997 Jun 26;336(26):1855-9 [9197213.001]
  • [Cites] Acta Gastroenterol Belg. 1998 Apr-Jun;61(2):189-91 [9658605.001]
  • [Cites] Hepatology. 1999 Mar;29(3):971-5 [10051505.001]
  • [Cites] Hepatology. 1999 Jun;29(6):1870-5 [10347132.001]
  • [Cites] Ann Intern Med. 1999 Aug 3;131(3):174-81 [10428733.001]
  • [Cites] N Engl J Med. 1999 Aug 19;341(8):556-62 [10451460.001]
  • [Cites] Semin Liver Dis. 1999;19(3):329-38 [10518312.001]
  • [Cites] Gastroenterology. 2004 Dec;127(6):1714-23 [15578509.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Jul;130(7):417-22 [15042359.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Oncogene. 2003 Jun 19;22(25):3911-6 [12813464.001]
  • [Cites] Gastroenterology. 2007 Jun;132(7):2557-76 [17570226.001]
  • [Cites] J Vasc Interv Radiol. 2007 Jul;18(7):856-61 [17609444.001]
  • [Cites] Science. 2007 Jul 6;317(5834):121-4 [17615358.001]
  • [Cites] Hepatology. 2008 Jan;47(1):82-9 [18008357.001]
  • [Cites] Antivir Ther. 2007;12(8):1295-303 [18240869.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Apr;6(4):459-64 [18387499.001]
  • [Cites] AJR Am J Roentgenol. 2008 May;190(5):1341-8 [18430853.001]
  • [Cites] Gastroenterology. 2008 Jul;135(1):111-21 [18505690.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] Hepatology. 2008 Sep;48(3):819-27 [18688876.001]
  • [Cites] Gastroenterology. 2008 Sep;135(3):947-55, 955.e1-5 [18639551.001]
  • [Cites] Ann Surg. 2008 Oct;248(4):617-25 [18936575.001]
  • [Cites] Gut. 2008 Nov;57(11):1592-6 [18669577.001]
  • [Cites] N Engl J Med. 2008 Dec 4;359(23):2429-41 [19052125.001]
  • [Cites] Ann Surg. 2009 Jan;249(1):20-5 [19106671.001]
  • [Cites] Gastroenterology. 2009 Jan;136(1):138-48 [18848939.001]
  • [Cites] Cancer. 2009 Feb 1;115(3):616-23 [19117042.001]
  • [Cites] Dig Dis Sci. 2009 Mar;54(3):661-9 [18649138.001]
  • [Cites] Eur Radiol. 2009 Apr;19(4):951-9 [18989675.001]
  • [Cites] Hepatology. 2005 Apr;41(4):707-16 [15795889.001]
  • [Cites] J Hepatol. 2005 May;42(5):760-77 [15826727.001]
  • [Cites] Semin Liver Dis. 2005;25(2):212-25 [15918149.001]
  • [Cites] Hepatology. 2005 Nov;42(5):1208-36 [16250051.001]
  • [Cites] Liver Transpl. 2005 Dec;11(12):1505-14 [16315294.001]
  • [Cites] J Gastrointest Surg. 2005 Dec;9(9):1207-15; discussion 1215 [16332475.001]
  • [Cites] JAMA. 2006 Jan 4;295(1):65-73 [16391218.001]
  • [Cites] Ann Surg. 2006 Mar;243(3):321-8 [16495695.001]
  • [Cites] Hepatology. 2006 May;43(5):891-902 [16628664.001]
  • [Cites] Gastroenterology. 2006 Aug;131(2):461-9 [16890600.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):792-800 [16904840.001]
  • [Cites] Ann Surg. 2007 Jan;245(1):36-43 [17197963.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Jan;5(1):118-23 [17008133.001]
  • [Cites] Ann Intern Med. 2007 May 1;146(9):649-56 [17470833.001]
  • [Cites] J Am Coll Surg. 2007 May;204(5):1016-27; discussion 1027-8 [17481532.001]
  • [Cites] Gastroenterology. 2007 May;132(5):1740-5 [17484871.001]
  • [Cites] J Clin Oncol. 2009 Mar 20;27(9):1485-91 [19224838.001]
  • [Cites] Gastroenterology. 2009 May;136(5):1601-8 [19208359.001]
  • [Cites] Hepatology. 2009 May;49(5):1563-70 [19399911.001]
  • [Cites] Gastroenterology. 2009 Jul;137(1):110-8 [19362088.001]
  • [Cites] Radiology. 2009 Sep;252(3):905-13 [19567647.001]
  • [Cites] J Natl Cancer Inst. 2009 Oct 7;101(19):1348-55 [19759364.001]
  • [Cites] Nat Rev Gastroenterol Hepatol. 2010 Aug;7(8):448-58 [20628345.001]
  • [Cites] Hepatology. 1999 Dec;30(6):1434-40 [10573522.001]
  • [Cites] Curr Top Microbiol Immunol. 2000;242:117-34 [10592658.001]
  • [Cites] Hepatogastroenterology. 1999 Nov-Dec;46(30):3216-22 [10626189.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Jan 19;267(2):581-7 [10631105.001]
  • [Cites] J Virol. 2000 Mar;74(6):2840-6 [10684300.001]
  • [Cites] Hepatology. 2000 Mar;31(3):777-82 [10706572.001]
  • [Cites] Hepatology. 2000 Apr;31(4):840-5 [10733537.001]
  • [Cites] Am J Pathol. 2000 Apr;156(4):1117-32 [10751335.001]
  • [Cites] Gut. 2001 Feb;48(2):251-9 [11156649.001]
  • [Cites] Lancet. 2001 Jan 20;357(9251):196-7 [11213099.001]
  • [Cites] J Hepatol. 2001 Feb;34(2):306-13 [11281561.001]
  • [Cites] Am J Gastroenterol. 2001 Apr;96(4):1160-3 [11316164.001]
  • [Cites] Aliment Pharmacol Ther. 2001 May;15(5):689-98 [11328263.001]
  • [Cites] Hepatology. 2001 Jun;33(6):1394-403 [11391528.001]
  • [Cites] J Hepatol. 2001 Apr;34(4):570-5 [11394657.001]
  • [Cites] J Hepatol. 2001 Apr;34(4):593-602 [11394661.001]
  • [Cites] J Natl Cancer Inst. 2001 Aug 1;93(15):1171-3 [11481390.001]
  • [Cites] Hepatology. 2001 Sep;34(3):529-34 [11526539.001]
  • [Cites] J Hepatol. 2001 Aug;35(2):254-8 [11580148.001]
  • [Cites] Ann Intern Med. 2001 Nov 6;135(9):796-800 [11694104.001]
  • [Cites] Science. 2001 Dec 14;294(5550):2376-8 [11743208.001]
  • [Cites] Hepatology. 2002 Jan;35(1):217-23 [11786979.001]
  • [Cites] Am J Epidemiol. 2002 Feb 15;155(4):323-31 [11836196.001]
  • [Cites] Oncology. 2002;62 Suppl 1:5-7 [11868786.001]
  • [Cites] Cancer. 2002 Mar 15;94(6):1747-52 [11920537.001]
  • [Cites] Am J Gastroenterol. 2002 Mar;97(3):734-44 [11922571.001]
  • [Cites] N Engl J Med. 2002 Apr 4;346(14):1074-82 [11932476.001]
  • [Cites] Hepatology. 2002 May;35(5):1164-71 [11981766.001]
  • [Cites] Lancet. 2002 May 18;359(9319):1734-9 [12049862.001]
  • [Cites] N Engl J Med. 2002 Jul 18;347(3):168-74 [12124405.001]
  • [Cites] Liver Transpl. 2002 Oct;8(10):873-83 [12360427.001]
  • [Cites] Hepatology. 2002 Nov;36(5):1206-13 [12395331.001]
  • [Cites] J Vasc Interv Radiol. 2002 Dec;13(12):1225-32 [12471186.001]
  • [Cites] J Hepatol. 2003 Feb;38(2):200-7 [12547409.001]
  • [Cites] Am J Epidemiol. 2003 Apr 15;157(8):674-82 [12697571.001]
  • [Cites] Oncogene. 2003 Jun 12;22(24):3813-20 [12802289.001]
  • [Cites] Liver Transpl. 2003 Jul;9(7):672-81 [12827551.001]
  • [Cites] Radiology. 2003 Jul;228(1):235-40 [12759473.001]
  • [Cites] J Biol Chem. 2003 Aug 22;278(34):31745-55 [12799372.001]
  • [Cites] Hepatology. 2003 Oct;38(4):1034-42 [14512891.001]
  • [Cites] Gastroenterology. 2003 Dec;125(6):1733-41 [14724826.001]
  • (PMID = 20937457.001).
  • [ISSN] 1557-9824
  • [Journal-full-title] Infectious disease clinics of North America
  • [ISO-abbreviation] Infect. Dis. Clin. North Am.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA100882; United States / NCI NIH HHS / CA / R56 CA100882; United States / NCI NIH HHS / CA / CA100882
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS550985; NLM/ PMC3949429
  •  go-up   go-down


49. Romero Marrero C, Ortiz AP, Pérez CM, Pérez J, Torres EA: Survival of hepatocellular carcinoma in Puerto Rico. P R Health Sci J; 2009 Jun;28(2):105-13
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival of hepatocellular carcinoma in Puerto Rico.
  • BACKGROUND: Blacks and Hispanics in the United States (US) have the lowest survival rates of hepatocellular carcinoma (HCC), mainly associated to the presence of advanced disease at diagnosis when intervention is least beneficial.
  • [MeSH-major] Carcinoma, Hepatocellular / mortality. Liver Neoplasms / mortality
  • [MeSH-minor] Adult. Age Factors. Aged. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Female. Hepatectomy. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Proportional Hazards Models. Puerto Rico / epidemiology. Registries. Risk. Statistics, Nonparametric. Survival Analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S248-60 [15508091.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S27-34 [15508094.001]
  • [Cites] N Engl J Med. 1999 Mar 11;340(10):745-50 [10072408.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Jul;130(7):417-22 [15042359.001]
  • [Cites] Radiology. 2005 Mar;234(3):961-7 [15665226.001]
  • [Cites] Clin Liver Dis. 2005 May;9(2):235-51, vi [15831271.001]
  • [Cites] Int J Epidemiol. 2005 Jun;34(3):593-9 [15802378.001]
  • [Cites] Hepatology. 2005 Nov;42(5):1208-36 [16250051.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Jan;4(1):104-10; quiz 4-5 [16431312.001]
  • [Cites] Gastroenterology. 2008 May;134(6):1752-63 [18471552.001]
  • [Cites] Arch Intern Med. 2007 Oct 8;167(18):1983-9 [17923599.001]
  • [Cites] Am J Gastroenterol. 2003 Nov;98(11):2535-42 [14638360.001]
  • [Cites] Ann Intern Med. 2003 Nov 18;139(10):817-23 [14623619.001]
  • [Cites] Clin Liver Dis. 2001 Feb;5(1):87-107, vi [11218921.001]
  • [Cites] Hepatology. 1999 Dec;30(6):1434-40 [10573522.001]
  • (PMID = 19530551.001).
  • [ISSN] 0738-0658
  • [Journal-full-title] Puerto Rico health sciences journal
  • [ISO-abbreviation] P R Health Sci J
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / R25 RR017589-08; United States / NCRR NIH HHS / RR / R25 RR17589; United States / NCI NIH HHS / CA / U54 CA096297; United States / NCRR NIH HHS / RR / R25 RR017589; United States / NCCDPHP CDC HHS / DP / U58 DP000782; United States / NCRR NIH HHS / RR / G12 RR003051; United States / NCI NIH HHS / CA / U54 CA096297-07; United States / NCRR NIH HHS / RR / G12RR03051; United States / NCRR NIH HHS / RR / G12 RR003051-24; United States / NIMHD NIH HHS / MD / G12 MD007600; United States / NCCDPHP CDC HHS / DP / U58DP000782-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Puerto Rico
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ NIHMS209148; NLM/ PMC3861879
  •  go-up   go-down


50. Nanashima A, Sumida Y, Abo T, Nagasaki T, Ohba K, Kinoshita H, Tobinaga S, Kenji T, Takeshita H, Hidaka S, Sawai T, Yasutake T, Nagayasu T: Surgical treatment and adjuvant chemotherapy in hepatocellular carcinoma patients with advanced vascular involvement. Hepatogastroenterology; 2008 Mar-Apr;55(82-83):627-32
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment and adjuvant chemotherapy in hepatocellular carcinoma patients with advanced vascular involvement.
  • BACKGROUND/AIMS: In advanced hepatocellular carcinoma (HCC) with vascular involvement of major vessels, patients have a poor prognosis after surgical treatment.
  • CONCLUSIONS: Complete surgical resection combined with main vascular resection could be safely performed in most advanced stage HCC patients and adjuvant chemotherapy in the early period after resection would be necessary, which may achieve longer survival in some patients even in the advanced stage.
  • [MeSH-major] Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / surgery. Hepatectomy. Liver Neoplasms / drug therapy. Liver Neoplasms / surgery. Vascular Neoplasms / drug therapy. Vascular Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18613421.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


51. Hwang JY, Jang BK, Kwon KM, Chung WJ, Park KS, Cho KB, Hwang JS, Ahn SH, Kim GC, Kim YH, Choi JS, Kwon JH: [Efficacy of hepatic arterial infusion therapy for advanced hepatocellular carcinoma using 5-fluorouracil, epirubicin and mitomycin-C]. Korean J Gastroenterol; 2005 Feb;45(2):118-24
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of hepatic arterial infusion therapy for advanced hepatocellular carcinoma using 5-fluorouracil, epirubicin and mitomycin-C].
  • BACKGROUND/AIM: Prognosis of advanced hepatocellular carcinoma (HCC) treated by conventional therapies has been considered to be poor.
  • The aim of this study was to evaluate the efficacy of hepatic arterial infusion therapy (HAIT) using FEM (5-fluorouracil, epirubicin, mitomycin-C) regimen for advanced HCC.
  • CONCLUSIONS: HAIT using FEM regimen is a useful therapeutic option for patients with advanced HCC with portal vein tumor thrombosis or ineffective response to other therapies.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Epirubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Infusion Pumps, Implantable. Infusions, Intra-Arterial. Male. Middle Aged. Mitomycin / administration & dosage. Survival Rate

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15725716.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil; FEM protocol
  •  go-up   go-down


52. Poh SB, Bai LY, Chen PM: Pegylated liposomal doxorubicin-based combination chemotherapy as salvage treatment in patients with advanced hepatocellular carcinoma. Am J Clin Oncol; 2005 Dec;28(6):540-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pegylated liposomal doxorubicin-based combination chemotherapy as salvage treatment in patients with advanced hepatocellular carcinoma.
  • OBJECTIVES: Effective chemotherapy with the least toxicity is important for patients with inoperable or advanced hepatocellular carcinoma.
  • CONCLUSION: Pegylated liposomal doxorubicin-based combination chemotherapy with capecitabine or gemcitabine was not effective as salvage therapy in advanced hepatocellular carcinoma.
  • Further effective systemic chemotherapy for patients with advanced hepatocellular carcinoma is warranted.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Antibiotics, Antineoplastic / administration & dosage. Antibiotics, Antineoplastic / adverse effects. Biomarkers, Tumor / blood. Capecitabine. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Doxorubicin / analogs & derivatives. Fatigue / chemically induced. Female. Fluorouracil / analogs & derivatives. Hepatitis B, Chronic / complications. Humans. Liposomes. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Middle Aged. Mucositis / chemically induced. Neoplasm Proteins / blood. Paresthesia / chemically induced. Polyethylene Glycols / administration & dosage. Polyethylene Glycols / adverse effects. Survival Analysis. Treatment Outcome. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16317261.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Biomarkers, Tumor; 0 / Liposomes; 0 / Neoplasm Proteins; 0 / alpha-Fetoproteins; 0 / liposomal doxorubicin; 0W860991D6 / Deoxycytidine; 30IQX730WE / Polyethylene Glycols; 6804DJ8Z9U / Capecitabine; 80168379AG / Doxorubicin; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


53. Sim MK, Kim DY, Park JY, Kim JK, Kim SA, Ahn SH, Chon CY, Moon YM, Won JY, Lee DY, Han KH: [Efficacy of repeated hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma with portal vein tumor thrombosis]. Korean J Hepatol; 2005 Sep;11(3):268-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of repeated hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma with portal vein tumor thrombosis].
  • BACKGROUND/AIMS: The aim of this study is to elucidate the efficacy of repeated hepatic arterial infusion chemotherapy (HAIC) and different chemotherapeutic regimens for treating patients having advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Hepatocellular / drug therapy. Hepatic Artery. Liver Neoplasms / drug therapy. Portal Vein. Venous Thrombosis / complications
  • [MeSH-minor] Adult. Cisplatin / administration & dosage. Female. Humans. Infusions, Intra-Arterial. Male. Middle Aged


54. Pinter M, Sieghart W, Graziadei I, Vogel W, Maieron A, Königsberg R, Weissmann A, Kornek G, Plank C, Peck-Radosavljevic M: Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist; 2009 Jan;14(1):70-6
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.
  • BACKGROUND: Few data are available on the safety and efficacy of sorafenib in patients with multifocal hepatocellular carcinoma (HCC) and advanced liver cirrhosis.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Cirrhosis / drug therapy. Liver Neoplasms / drug therapy. Pyridines / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Niacinamide / analogs & derivatives. Phenylurea Compounds. Protein Kinase Inhibitors / adverse effects. Protein Kinase Inhibitors / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Oncologist. 2009 Jan;14(1):67-9 [19147690.001]
  • (PMID = 19144684.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


55. Jang BK, Chung WJ, Park KS, Cho KB, Hwang JS, Ahn SH, Kim YH, Choi JS, Kwon JH: [The efficacy of hepatic arterial infusion therapy for advanced hepatocellular carcinoma according to extrahepatic collateral feeding vessels]. Korean J Hepatol; 2005 Dec;11(4):359-70
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The efficacy of hepatic arterial infusion therapy for advanced hepatocellular carcinoma according to extrahepatic collateral feeding vessels].
  • BACKGROUND/AIMS: Despite the poor response rate of 20-30%, hepatic arterial infusion therapy (HAIT) has been often tried for advanced hepatocellular carcinoma with portal vein tumor thrombosis or ineffective response to other treatments.
  • CONCLUSIONS: Hepatic arterial infusion therapy may be useful therapeutic option for patients with advanced HCC, especially in those that do not have extrahepatic collateral feeding vessel or anatomical variant.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / blood supply. Carcinoma, Hepatocellular / drug therapy. Hepatic Artery. Infusions, Intra-Arterial. Liver Neoplasms / blood supply. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Collateral Circulation. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16380665.001).
  • [ISSN] 1738-222X
  • [Journal-full-title] The Korean journal of hepatology
  • [ISO-abbreviation] Korean J Hepatol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


56. Faivre S, Raymond E, Boucher E, Douillard J, Lim HY, Kim JS, Zappa M, Lanzalone S, Lin X, Deprimo S, Harmon C, Ruiz-Garcia A, Lechuga MJ, Cheng AL: Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol; 2009 Aug;10(8):794-800
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study.
  • BACKGROUND: Hepatocellular carcinoma (HCC) tumour spread is partly dependent on neoangiogenesis.
  • In this open-label, multicentre, phase II trial done in Europe and Asia, sunitinib, a multitargeted tyrosine-kinase inhibitor with anti-angiogenic properties, was assessed in patients with advanced unresectable HCC.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Indoles / therapeutic use. Liver Neoplasms / drug therapy. Pyrroles / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet Oncol. 2009 Aug;10(8):743-4 [19647195.001]
  • (PMID = 19586800.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00247676
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Indoles; 0 / Pyrroles; 0 / sunitinib
  •  go-up   go-down


57. Park JY, Ahn SH, Yoon YJ, Kim JK, Lee HW, Lee DY, Chon CY, Moon YM, Han KH: Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer; 2007 Jul 1;110(1):129-37
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma.
  • BACKGROUND: Hepatic arterial infusion chemotherapy (HAIC) has often been selected as a therapeutic option for patients with advanced hepatocellular carcinoma (HCC).
  • The objective of the current study was to evaluate the efficacy and safety of repetitive HAIC with high-dose 5-fluorouracil (5-FU) and cisplatin given for 3 days in patients with advanced HCC.
  • METHODS: Between January 2001 and December 2004, a total of 41 patients with unresectable advanced HCC were enrolled.
  • CONCLUSIONS: HAIC with high-dose 5-FU and cisplatin given for 3 days achieved effective and safe results in patients with advanced HCC.
  • Therefore, repetitive short-course HAIC with high-dose 5-FU and cisplatin may be useful as an alternative therapeutic option for patients with advanced HCC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Anemia / chemically induced. Cisplatin / administration & dosage. Cisplatin / adverse effects. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Infusions, Intra-Arterial. Kaplan-Meier Estimate. Leukopenia / chemically induced. Male. Middle Aged. Nausea / chemically induced. Neutropenia / chemically induced. Prognosis. Time Factors. Treatment Outcome. Vomiting / chemically induced

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 American Cancer Society.
  • (PMID = 17508408.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


58. Hsu CH, Shen YC, Lin ZZ, Chen PJ, Shao YY, Ding YH, Hsu C, Cheng AL: Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. J Hepatol; 2010 Jul;53(1):126-31
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma.
  • BACKGROUND & AIMS: Sorafenib, a multi-kinase inhibitor with anti-angiogenic activity, was recently approved for the treatment of advanced hepatocellular carcinoma (HCC).
  • This phase II study evaluated the efficacy and safety of combining metronomic tegafur/uracil with sorafenib in patients with advanced HCC.
  • METHODS: Patients with histologically- or cytologically-proven HCC and Child-Pugh class A liver function were treated with sorafenib (400mg twice daily) and tegafur/uracil (125 mg/m(2) based on tegafur twice daily) continuously as first-line therapy for metastatic or locally advanced disease that could not be treated by loco-regional therapies.
  • CONCLUSIONS: Metronomic chemotherapy with tegafur/uracil can be safely combined with sorafenib and shows preliminary activity to improve the efficacy of sorafenib in advanced HCC patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anorexia / chemically induced. Benzenesulfonates / administration & dosage. Diarrhea / chemically induced. Disease-Free Survival. Drug Eruptions / etiology. Fatigue / chemically induced. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Niacinamide / analogs & derivatives. Phenylurea Compounds. Protein Kinase Inhibitors / administration & dosage. Pyridines / administration & dosage. Tegafur / administration & dosage. Uracil / administration & dosage

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20416968.001).
  • [ISSN] 1600-0641
  • [Journal-full-title] Journal of hepatology
  • [ISO-abbreviation] J. Hepatol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 1548R74NSZ / Tegafur; 25X51I8RD4 / Niacinamide; 56HH86ZVCT / Uracil; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


59. Zhu AX, Stuart K, Blaszkowsky LS, Muzikansky A, Reitberg DP, Clark JW, Enzinger PC, Bhargava P, Meyerhardt JA, Horgan K, Fuchs CS, Ryan DP: Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer; 2007 Aug 1;110(3):581-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma.
  • BACKGROUND: Epidermal growth factor receptor (EGFR) and ligand expression is frequently seen in hepatocellular carcinoma (HCC).
  • A phase 2 study was performed with cetuximab, a chimeric monoclonal antibody that binds specifically to EGFR, in patients with advanced HCC.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Humanized. Cetuximab. Female. Humans. Male. Middle Aged. Receptor, Epidermal Growth Factor / metabolism. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 American Cancer Society.
  • (PMID = 17583545.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; PQX0D8J21J / Cetuximab
  •  go-up   go-down


60. Shiah HS, Chao Y, Chen LT, Yao TJ, Huang JD, Chang JY, Chen PJ, Chuang TR, Chin YH, Whang-Peng J, Liu TW: Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol; 2006 Nov;58(5):654-64
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma.
  • PURPOSE: To evaluate the dose-limiting toxicities (DLT), maximum tolerated dose (MTD), and pharmacokinetics of thalidomide in patients with advanced hepatocellular carcinoma (HCC).
  • METHODS: Patients with advanced HCC who were not feasible for definitive local therapy were eligible.
  • [MeSH-major] Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Thalidomide / pharmacokinetics
  • [MeSH-minor] Administration, Oral. Adult. Aged. Alanine Transaminase / blood. Angiogenesis Inhibitors / adverse effects. Angiogenesis Inhibitors / pharmacokinetics. Angiogenesis Inhibitors / therapeutic use. Area Under Curve. Biological Availability. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Half-Life. Humans. Male. Metabolic Clearance Rate. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16520988.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 4Z8R6ORS6L / Thalidomide; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


61. Ueshima K, Kudo M, Nagai T, Tatsumi C, Ueda T, Takahashi S, Hatanaka K, Kitai S, Ishikawa E, Inoue T, Hagiwara S, Minami Y, Chung H: Combination therapy with S-1 and pegylated interferon alpha for advanced hepatocellular carcinoma. Oncology; 2008;75 Suppl 1:106-13
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination therapy with S-1 and pegylated interferon alpha for advanced hepatocellular carcinoma.
  • PURPOSE: There are currently no effective treatments for patients with advanced hepatocellular carcinoma (HCC) with vascular invasion or extrahepatic metastases.
  • We evaluated the efficacy and safety of combination therapy with S-1 and pegylated interferon (PEG-IFN)-alpha for advanced HCC.
  • CONCLUSION: Combination therapy with S-1 and PEG-IFN is effective and feasible, and is therefore a promising regimen for advanced HCC.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Hepatocellular / drug therapy. Interferon-alpha / administration & dosage. Liver Neoplasms / drug therapy. Oxonic Acid / administration & dosage. Polyethylene Glycols / administration & dosage. Tegafur / administration & dosage
  • [MeSH-minor] Adult. Aged. Disease Progression. Drug Combinations. Drug Therapy, Combination. Feasibility Studies. Female. Humans. Male. Middle Aged. Recombinant Proteins. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 19092279.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Combinations; 0 / Interferon-alpha; 0 / Recombinant Proteins; 0 / peginterferon alfa-2a; 0 / peginterferon alfa-2b; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 30IQX730WE / Polyethylene Glycols; 5VT6420TIG / Oxonic Acid; 76543-88-9 / interferon alfa-2a; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


62. Wörns MA, Weinmann A, Pfingst K, Schulte-Sasse C, Messow CM, Schulze-Bergkamen H, Teufel A, Schuchmann M, Kanzler S, Düber C, Otto G, Galle PR: Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol; 2009 May-Jun;43(5):489-95
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
  • GOALS AND BACKGROUND: The multikinase inhibitor sorafenib provides survival benefit for patients with advanced hepatocellular carcinoma (HCC) and liver cirrhosis (LCI) Child-Pugh A.
  • We report our experiences with sorafenib in advanced HCC, particularly in patients with LCI Child-Pugh B/C, where only limited data are available in regard to safety and efficacy of sorafenib.
  • METHODS: Thirty-four patients with advanced HCC were treated with sorafenib regardless of liver function and prior anticancer therapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Cirrhosis / pathology. Liver Neoplasms / drug therapy. Protein Kinase Inhibitors / therapeutic use. Pyridines / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Niacinamide / analogs & derivatives. Patient Selection. Phenylurea Compounds. Prospective Studies. Risk Assessment. Severity of Illness Index. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Gastroenterol. 2009 May-Jun;43(5):389-90 [19564813.001]
  • (PMID = 19247201.001).
  • [ISSN] 1539-2031
  • [Journal-full-title] Journal of clinical gastroenterology
  • [ISO-abbreviation] J. Clin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


63. Collette S, Bonnetain F, Paoletti X, Doffoel M, Bouché O, Raoul JL, Rougier P, Masskouri F, Bedenne L, Barbare JC: Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials. Ann Oncol; 2008 Jun;19(6):1117-26
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials.
  • OBJECTIVE: The objective of this study was to assess the performance of three staging systems [Okuda, Cancer of the Liver Italian Program (CLIP) and Barcelona Clinic Liver Cancer group (BCLC)], for predicting survival in patients with hepatocellular carcinoma (HCC) and to explore how to improve prognostic classification among French patients with HCC whose main etiology is alcoholic cirrhosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18303031.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  •  go-up   go-down


64. Nagai H, Matsui T, Kanayama M, Momiyama K, Shizawa K, Wakui N, Shinohara M, Watanabe M, Iida K, Ishii K, Igarashi Y, Sumino Y: Hepatotoxicity of intra-arterial combination chemotherapy in patients with liver cirrhosis and advanced hepatocellular carcinoma. Cancer Chemother Pharmacol; 2010 Nov;66(6):1123-9
Hazardous Substances Data Bank. HYALURONIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatotoxicity of intra-arterial combination chemotherapy in patients with liver cirrhosis and advanced hepatocellular carcinoma.
  • PURPOSE: We have previously reported that 24-h intra-arterial combination chemotherapy (IACC) prolongs the survival of patients with advanced hepatocellular carcinoma (aHCC).
  • METHODS: Twenty-one adult Japanese patients (20 men and 1 woman) with aHCC and LC underwent IACC between 2004 and 2007 at our hospital.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Carcinoma, Hepatocellular / drug therapy. Infusions, Intra-Arterial / adverse effects. Liver Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20180123.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Collagen Type IV; 0 / Peptide Fragments; 0 / Procollagen; 0 / Serum Albumin; 0 / procollagen Type III-N-terminal peptide; 9004-61-9 / Hyaluronic Acid; EC 2.6.1.- / Transaminases; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


65. Thomas MB, Morris JS, Chadha R, Iwasaki M, Kaur H, Lin E, Kaseb A, Glover K, Davila M, Abbruzzese J: Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol; 2009 Feb 20;27(6):843-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.
  • PURPOSE: The study objective was to determine the proportion of patients with hepatocellular carcinoma (HCC) treated with the combination of bevacizumab (B) and erlotinib (E) who were alive and progression free at 16 weeks (16-week progression-free survival [PFS16]) of continuous therapy.
  • PATIENTS AND METHODS: Patients who had advanced HCC that was not amenable to surgical or regional therapies, up to one prior systemic treatment; Childs-Pugh score A or B liver function; Eastern Cooperative Oncology Group performance status 0, 1, or 2 received B 10 mg/kg every 14 days and E 150 mg orally daily, continuously, for 28-day cycles.
  • CONCLUSION: The combination of B + E in patients who had advanced HCC showed significant, clinically meaningful antitumor activity.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Quinazolines / administration & dosage
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Humanized. Bevacizumab. Drug Therapy, Combination. Erlotinib Hydrochloride. Female. Humans. Male. Middle Aged. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Vascular Endothelial Growth Factor A / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2009 Feb 20;27(6):833-5 [19139428.001]
  • [ErratumIn] J Clin Oncol. 2009 Jul 1;27(19):3263. Lin, Elinor [corrected to Lin, E]
  • (PMID = 19139433.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Quinazolines; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


66. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB: Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol; 2006 Sep 10;24(26):4293-300
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
  • PURPOSE: This phase II study of sorafenib, an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases, assessed efficacy, toxicity, pharmacokinetics, and biomarkers in advanced hepatocellular carcinoma (HCC) patients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Protein Kinase Inhibitors / therapeutic use. Pyridines / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Disease-Free Survival. Drug Administration Schedule. Extracellular Signal-Regulated MAP Kinases / blood. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Neoplasm Staging. Niacinamide / analogs & derivatives. Phenylurea Compounds. Predictive Value of Tests. RNA, Neoplasm / blood. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16908937.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Biomarkers, Tumor; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 0 / RNA, Neoplasm; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  •  go-up   go-down


67. Li B, Yuan Y, Chen G, He L, Zhang Y, Li J, Li G, Lau WY: Application of tumor-node-metastasis staging 2002 version in locally advanced hepatocellular carcinoma: is it predictive of surgical outcome? BMC Cancer; 2010;10:535
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Application of tumor-node-metastasis staging 2002 version in locally advanced hepatocellular carcinoma: is it predictive of surgical outcome?
  • BACKGROUND: Locally advanced (pT3-4N0M0) hepatocellular carcinoma (HCC) is a heterogeneous group of tumors, which consists of four different categories, including HCC with "multiple tumors more than 5 cm", "major vascular invasion", "invasion of adjacent organs", and "perforation of visceral peritoneum".
  • The aim of our study was to verify whether the 2002 version of the Tumor-Node-Metastasis staging system could predict surgical outcomes in patients with locally advanced HCC.
  • Overall survival (OS) and cumulative recurrence rate (CRR) of the four categories of locally advanced HCC patients were compared.
  • RESULTS: In multivariate analysis, major vascular invasion was identified as the most significant factor (HR = 3.291, 95% CI 2.362-4.584, P < 0.001) followed by cirrhosis status on OS, and was found to be the only independent factor of CRR (HR = 2.242, 95% CI 1.811-3.358, P < 0.001) in patients with locally advanced HCC.
  • Among the four categories of locally advanced HCC, OS was significantly worse, and CRR was significantly higher in patients with HCC with major vascular invasion (pT3) than with multiple tumors more than 5 cm (pT3); or tumor invasion of adjacent organs (pT4); or perforation of visceral peritoneum (pT4).
  • There is a need to redefine the T classification and to stratify locally advanced HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Carcinoma, Hepatocellular / surgery. Liver Neoplasms / diagnosis. Liver Neoplasms / surgery. Neoplasm Staging / methods
  • [MeSH-minor] Adult. Female. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Metastasis. Recurrence. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2007 Jun;132(7):2557-76 [17570226.001]
  • [Cites] Ann Surg. 2007 Jun;245(6):909-22 [17522517.001]
  • [Cites] J Hepatol. 2008;48 Suppl 1:S20-37 [18304676.001]
  • [Cites] Gastroenterology. 2008 Jun;134(7):1908-16 [18549877.001]
  • [Cites] Arch Surg. 2008 Jun;143(6):538-43; discussion 543 [18559745.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] J Gastrointest Surg. 2008 Sep;12(9):1540-7 [18629593.001]
  • [Cites] Hepatology. 2008 Oct;48(4):1312-27 [18821591.001]
  • [Cites] Eur J Surg Oncol. 2009 Feb;35(2):174-9 [18325724.001]
  • [Cites] Surg Today. 2009;39(10):833-43 [19784720.001]
  • [Cites] Hepatology. 2000 Apr;31(4):864-71 [10733541.001]
  • [Cites] Cancer. 2000 Aug 1;89(3):500-7 [10931448.001]
  • [Cites] J Pathol. 2000 Sep;192(1):43-51 [10951399.001]
  • [Cites] Hepatogastroenterology. 2001 Jan-Feb;48(37):46-50 [11268996.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1527-36 [11896101.001]
  • [Cites] Ann Surg. 2003 Mar;237(3):376-83 [12616122.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Jan;12(1):65-75, ix [12735130.001]
  • [Cites] Hepatogastroenterology. 2003 Jul-Aug;50(52):1078-84 [12845986.001]
  • [Cites] Cancer. 2004 Jan 1;100(1):1-5 [14692017.001]
  • [Cites] Hepatology. 1991 Aug;14(2):262-8 [1650325.001]
  • [Cites] Hepatology. 1992 Jul;16(1):112-7 [1377657.001]
  • [Cites] J Nucl Med. 1994 Nov;35(11):1782-7 [7525901.001]
  • [Cites] Br J Surg. 1995 Feb;82(2):264-6 [7749707.001]
  • [Cites] Surgery. 1996 May;119(5):517-22 [8619206.001]
  • [Cites] Eur J Surg Oncol. 1996 Oct;22(5):516-20 [8903496.001]
  • [Cites] Ann Surg. 1998 Mar;227(3):433-9 [9527067.001]
  • [Cites] Ann Surg. 1999 Feb;229(2):216-22 [10024103.001]
  • [Cites] Surgery. 2005 Apr;137(4):403-10 [15800485.001]
  • [Cites] Ann Surg Oncol. 2005 May;12(5):364-73 [15915370.001]
  • [Cites] Ann Surg. 2006 Feb;243(2):229-35 [16432356.001]
  • [Cites] Int J Cancer. 2007 Jun 15;120(12):2650-5 [17304512.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • (PMID = 20925965.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2958946
  •  go-up   go-down


68. Nakamura S, Nouso K, Noguchi Y, Higashi T, Ono T, Jungbluth A, Chen YT, Old LJ, Nakayama E, Shiratori Y: Expression and immunogenicity of NY-ESO-1 in hepatocellular carcinoma. J Gastroenterol Hepatol; 2006 Aug;21(8):1281-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and immunogenicity of NY-ESO-1 in hepatocellular carcinoma.
  • BACKGROUND AND AIM: The present study was designed to investigate the expression of and humoral response against NY-ESO-1 in patients with hepatocellular carcinoma and to analyze the relationship between expression of NY-ESO-1 mRNA and clinicopathological features.
  • METHODS: NY-ESO-1 mRNA and protein expression in surgically resected hepatocellular carcinoma specimens, adjacent non-cancerous liver and non-tumor bearing liver were examined by reverse transcription-polymerase chain reaction and immunohistochemical staining using a monoclonal antibody against NY-ESO-1 (ES121), respectively.
  • RESULTS: NY-ESO-1 mRNA was detected in 18 of 41 (43.9%) hepatocellular carcinomas.
  • Immunohistochemistry revealed heterogeneous expression of NY-ESO-1 protein in three of 18 NY-ESO-1 mRNA-positive hepatocellular carcinomas.
  • None of 23 NY-ESO-1 mRNA-negative hepatocellular carcinomas expressed NY-ESO-1 protein.
  • Antibody against NY-ESO-1 protein was detected in two of 92 patients with hepatocellular carcinoma.
  • CONCLUSIONS: The present study has demonstrated the expression of NY-ESO-1 mRNA in hepatocellular carcinoma and NY-ESO-1 antibody production in patients with advanced hepatocellular carcinoma.
  • Although the enhancement of NY-ESO-1 protein expression and the activation of immune response of the patients with hepatocellular carcinoma are necessary, NY-ESO-1 has the potential to be a good target molecule for immunotherapy against advanced hepatocellular carcinoma.
  • [MeSH-major] Antigens, Neoplasm / genetics. Carcinoma, Hepatocellular / genetics. Liver Neoplasms / genetics. Membrane Proteins / genetics
  • [MeSH-minor] Adult. Aged. DNA, Neoplasm / analysis. Female. Gene Expression. Humans. Immunohistochemistry. Liver / pathology. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16872310.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / CTAG1B protein, human; 0 / DNA, Neoplasm; 0 / Membrane Proteins
  •  go-up   go-down


69. Boige V, Raoul JL, Pignon JP, Bouché O, Blanc JF, Dahan L, Jouve JL, Dupouy N, Ducreux M, Fédération Francophone de Cancérologie Digestive: Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial. Br J Cancer; 2007 Oct 8;97(7):862-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial.
  • Evaluation of new drug combinations is needed to improve patients' prognosis in advanced hepatocellular carcinoma (HCC).
  • Capecitabine plus oxaliplatin regimen showed modest anti-tumour activity with tolerable toxicities in patients with advanced HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / drug therapy. Deoxycytidine / analogs & derivatives. Fluorouracil / analogs & derivatives. Liver Neoplasms / drug therapy. Organoplatinum Compounds / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols. Drug Combinations. Female. Humans. Male. Middle Aged. Prognosis. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Pharmacol. 2000;45(4):291-7 [10755317.001]
  • [Cites] Cancer. 2007 Apr 1;109(7):1384-90 [17330837.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):153-6 [11668491.001]
  • [Cites] J Clin Oncol. 2001 Nov 1;19(21):4097-106 [11689577.001]
  • [Cites] Cancer. 2002 Jan 15;94(2):421-7 [11905412.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1759-66 [11919232.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2084-91 [15169795.001]
  • [Cites] Lancet Oncol. 2004 Jul;5(7):409-18 [15231247.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):578-86 [15274071.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S179-88 [15508083.001]
  • [Cites] Biometrics. 1982 Mar;38(1):143-51 [7082756.001]
  • [Cites] Cancer. 1988 Aug 1;62(3):479-83 [2839280.001]
  • [Cites] J Natl Cancer Inst. 1990 Jun 20;82(12):1046-50 [2348469.001]
  • [Cites] Hepatogastroenterology. 1998 Aug;45 Suppl 3:1259-63 [9730385.001]
  • [Cites] Hepatology. 1998 Sep;28(3):751-5 [9731568.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Eur J Cancer. 1998 Jul;34(8):1274-81 [9849491.001]
  • [Cites] Clin Cancer Res. 1999 Jul;5(7):1696-702 [10430071.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6657-63 [16170173.001]
  • [Cites] J Natl Cancer Inst. 2005 Oct 19;97(20):1532-8 [16234567.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Apr;57(4):436-42 [16049620.001]
  • [Cites] BMC Cancer. 2006;6:3 [16396674.001]
  • [Cites] Br J Cancer. 2006 Apr 10;94(7):959-63 [16552439.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4293-300 [16908937.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):2938-47 [10944126.001]
  • (PMID = 17876335.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Organoplatinum Compounds; 0W860991D6 / Deoxycytidine; U3P01618RT / Fluorouracil; XELOX
  • [Other-IDs] NLM/ PMC2360397
  •  go-up   go-down


70. Nagai H, Kanayama M, Higami K, Momiyama K, Ikoma A, Okano N, Matsumaru K, Watanabe M, Ishii K, Sumino Y, Miki K: Twenty-four hour intra-arterial infusion of 5-fluorouracil, cisplatin, and leucovorin is more effective than 6-hour infusion for advanced hepatocellular carcinoma. World J Gastroenterol; 2007 Jan 14;13(2):280-4
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Twenty-four hour intra-arterial infusion of 5-fluorouracil, cisplatin, and leucovorin is more effective than 6-hour infusion for advanced hepatocellular carcinoma.
  • AIM: To evaluate the time dependence of intra-arterial 5-fluorouracil (5-FU) therapy for advanced hepatocellular carcinoma (aHCC).
  • METHODS: Thirty-seven adult Japanese patients who had aHCC and liver cirrhosis were treated with combined intra-arterial 5-FU, cisplatin (CDDP), and leucovorin (LV).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / mortality. Liver Neoplasms / drug therapy. Liver Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1986 Dec;83(23):8923-5 [3466165.001]
  • [Cites] Hepatology. 2004 Dec;40(6):1396-405 [15565571.001]
  • [Cites] J Clin Oncol. 1989 Oct;7(10):1407-18 [2476530.001]
  • [Cites] Am J Clin Oncol. 1989 Dec;12(6):486-90 [2686394.001]
  • [Cites] J Clin Oncol. 1994 Jan;12(1):14-20 [7677801.001]
  • [Cites] Cancer Chemother Pharmacol. 1994;33 Suppl:S134-8 [8137474.001]
  • [Cites] Cancer. 2000 Dec 1;89(11):2266-73 [11147597.001]
  • [Cites] Hepatology. 2001 Sep;34(3):529-34 [11526539.001]
  • [Cites] Gut. 2002 Jun;50(6):881-5 [12010894.001]
  • [Cites] J Gastroenterol. 2003;38(3):207-15 [12673442.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2C):1719-22 [12820447.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2C):1891-7 [12820474.001]
  • [Cites] Gan To Kagaku Ryoho. 2003 Dec;30(13):2077-81 [14712768.001]
  • [Cites] Cancer. 1984 Oct 1;54(7):1461-5 [6205743.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):918-28 [2990661.001]
  • [Cites] Cancer Treat Rep. 1985 Dec;69(12):1391-8 [4075316.001]
  • [Cites] Oncology. 1995 Jul-Aug;52(4):295-9 [7777243.001]
  • [Cites] Hepatology. 1998 Sep;28(3):751-5 [9731568.001]
  • [Cites] Oncol Rep. 1999 May-Jun;6(3):587-91 [10203596.001]
  • [Cites] J Biol Chem. 1959 May;234(5):1255-62 [13654358.001]
  • [Cites] Cancer. 1989 Mar 15;63(6 Suppl):1026-30 [2465076.001]
  • (PMID = 17226909.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC4065958
  •  go-up   go-down


71. Hsu CH, Yang TS, Hsu C, Toh HC, Epstein RJ, Hsiao LT, Chen PJ, Lin ZZ, Chao TY, Cheng AL: Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br J Cancer; 2010 Mar 16;102(6):981-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma.
  • BACKGROUND: Molecularly targeted agents with anti-angiogenic activity, including bevacizumab, have demonstrated clinical activity in patients with advanced/metastatic hepatocellular carcinoma (HCC).
  • METHODS: Histologically proven/clinically diagnosed advanced HCC patients received bevacizumab 7.5 mg kg(-1) on day 1 and capecitabine 800 mg m(-2) twice daily on days 1-14 every 3 weeks as first-line therapy.
  • CONCLUSION: The bevacizumab-capecitabine combination shows good tolerability and modest anti-tumour activity in patients with advanced HCC.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Deoxycytidine / analogs & derivatives. Fluorouracil / analogs & derivatives. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Humanized. Bevacizumab. Capecitabine. Disease Progression. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Survival Analysis. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Dec 1;89(11):2266-73 [11147597.001]
  • [Cites] Contemp Clin Trials. 2010 Jan;31(1):55-61 [19737631.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):578-86 [15274071.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7099-109 [15466206.001]
  • [Cites] Stat Med. 1994 Sep 15;13(17):1727-36 [7997706.001]
  • [Cites] Hepatology. 1998 Jul;28(1):68-77 [9657098.001]
  • [Cites] Clin Cancer Res. 1999 Jul;5(7):1696-702 [10430071.001]
  • [Cites] Expert Opin Investig Drugs. 2004 Dec;13(12):1555-68 [15566313.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):792-9 [15681523.001]
  • [Cites] Gut. 2005 Mar;54(3):411-8 [15710992.001]
  • [Cites] Ann Oncol. 2005 Aug;16(8):1289-96 [15890665.001]
  • [Cites] Aliment Pharmacol Ther. 2005 Aug 1;22(3):217-26 [16091059.001]
  • [Cites] J Clin Oncol. 2006 Apr 20;24(12):1898-903 [16622265.001]
  • [Cites] Oncologist. 2006 Jul-Aug;11(7):790-800 [16880238.001]
  • [Cites] Nat Rev Drug Discov. 2006 Oct;5(10):835-44 [17016424.001]
  • [Cites] Cancer Lett. 2006 Oct 28;242(2):151-67 [16564617.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] Gastroenterology. 2007 Jun;132(7):2557-76 [17570226.001]
  • [Cites] Am J Gastroenterol. 2007 Aug;102(8):1661-70; quiz 1660, 1671 [17555459.001]
  • [Cites] J Natl Cancer Inst. 2008 May 21;100(10):698-711 [18477802.001]
  • [Cites] Ann Oncol. 2008 Jun;19(6):1117-26 [18303031.001]
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):2992-8 [18565886.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] Lancet Oncol. 2009 Jan;10(1):25-34 [19095497.001]
  • [Cites] J Clin Oncol. 2009 Jan 20;27(3):446-52 [19064965.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):843-50 [19139433.001]
  • [Cites] Oncologist. 2009 Jul;14(7):717-25 [19581525.001]
  • [Cites] Anticancer Drugs. 2004 Feb;15(2):137-43 [15075669.001]
  • (PMID = 20160718.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0W860991D6 / Deoxycytidine; 2S9ZZM9Q9V / Bevacizumab; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2844032
  •  go-up   go-down


72. Chern MC, Chuang VP, Cheng T, Lin ZH, Lin YM: Transcatheter arterial chemoembolization for advanced hepatocellular carcinoma with inferior vena cava and right atrial tumors. Cardiovasc Intervent Radiol; 2008 Jul-Aug;31(4):735-44
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcatheter arterial chemoembolization for advanced hepatocellular carcinoma with inferior vena cava and right atrial tumors.
  • Advanced hepatocelluar carcinoma (HCC) with invasion of venous systems usually indicates not only a poor prognosis but also a contraindication for transcatheter arterial chemoembolization (TACE).
  • This study evaluated the feasibility of TACE for advanced HCC with inferior vena cava (IVC) and right atrium (RA) tumors and, also, to search for the ideal embolization particle size.
  • In conclusion, TACE is a safe and effective treatment for advanced HCC with IVC and RA tumors, and small Ivalon particles (47-180 microm) are superior to large ones (>180 microm).
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic / methods. Heart Neoplasms / therapy. Liver Neoplasms / therapy. Neoplastic Cells, Circulating / pathology. Vascular Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Angiography. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Catheterization / methods. Cohort Studies. Female. Heart Atria / pathology. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Palliative Care. Prognosis. Risk Assessment. Survival Analysis. Tomography, X-Ray Computed. Treatment Outcome. Vena Cava, Inferior

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cardiovasc Intervent Radiol. 2009 Nov;32(6):1321
  • (PMID = 18427894.001).
  • [ISSN] 1432-086X
  • [Journal-full-title] Cardiovascular and interventional radiology
  • [ISO-abbreviation] Cardiovasc Intervent Radiol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Li BG, Wen H, Guo Z, Wang HT: [Evidenced-based clinical practice of interventional therapy for advanced hepatocellular carcinoma:2-year follow-up results in 59 cases]. Zhonghua Yi Xue Za Zhi; 2010 May 11;90(18):1255-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evidenced-based clinical practice of interventional therapy for advanced hepatocellular carcinoma:2-year follow-up results in 59 cases].
  • OBJECTIVE: To explore the methods of evidence-based medicine to determine objectives and evaluate the efficacy of interventional therapy for advanced hepatocellular carcinoma.
  • The searching subjects were hepatocellular carcinoma, interventional therapy, systematic review and meta-analysis etc.
  • A total of 119 cases of hepatocellular carcinoma were included.
  • The 2-year follow-up results confirmed that the evidence-based regimes were more appropriate for advanced hepatocellular carcinoma.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic. Evidence-Based Medicine. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Male. Meta-Analysis as Topic. Middle Aged. Randomized Controlled Trials as Topic. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20646598.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


74. Cabrera R, Nelson DR: Review article: the management of hepatocellular carcinoma. Aliment Pharmacol Ther; 2010 Feb 15;31(4):461-76
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review article: the management of hepatocellular carcinoma.
  • BACKGROUND: Hepatocellular carcinoma is the leading cause of death in cirrhosis.
  • A majority of patients present at an advanced stage with poor prognosis.
  • AIM: To review the current screening, diagnosis and management strategies involved in hepatocellular carcinoma.
  • RESULTS: Hepatocellular carcinoma is dramatically increasing in incidence that is mostly attributed to chronic hepatitis C and non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and its clinical phenotype diabetes and obesity.
  • Cirrhosis is the major predisposing risk factor and its presence necessitates close surveillance for hepatocellular carcinoma with serial imaging studies.
  • Hepatocellular carcinoma can be diagnosed by its unique radiological behaviour of arterial enhancement and washout on delayed images.
  • The Barcelona Clinic Liver Cancer staging classification system is a clinically useful algorithm for the management of patients with hepatocellular carcinoma.
  • A multidisciplinary approach is critical to the successful management of hepatocellular carcinoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Carcinoma, Hepatocellular / diagnosis. Carcinoma, Hepatocellular / therapy. Liver Neoplasms / diagnosis. Liver Neoplasms / therapy. Pyridines / therapeutic use
  • [MeSH-minor] Ablation Techniques. Adult. African Continental Ancestry Group. Asian Continental Ancestry Group. Biopsy. Chemoembolization, Therapeutic. Contrast Media. Drug Eruptions / prevention & control. Female. Health Care Costs. Hepatitis B, Chronic / complications. Hepatitis B, Chronic / epidemiology. Hepatitis C, Chronic / complications. Hepatitis C, Chronic / epidemiology. Humans. Incidence. Liver Cirrhosis / complications. Liver Cirrhosis / mortality. Liver Transplantation. Male. Middle Aged. Neoplasm Staging / methods. Neovascularization, Pathologic / drug therapy. Niacinamide / analogs & derivatives. Phenylurea Compounds. Population Surveillance. Practice Guidelines as Topic. Quality of Life. Randomized Controlled Trials as Topic. Recurrence. Risk Factors. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome. United States / epidemiology. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Aliment Pharmacol Ther. 2010 May;31(10):1153-4 [20518755.001]
  • (PMID = 19925500.001).
  • [ISSN] 1365-2036
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Contrast Media; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  • [Number-of-references] 96
  •  go-up   go-down


75. Tsai AL, Burke CT, Kennedy AS, Moore DT, Mauro MA, Dixon RD, Stavas JM, Bernard SA, Khandani AH, O'Neil BH: Use of yttrium-90 microspheres in patients with advanced hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol; 2010 Sep;21(9):1377-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of yttrium-90 microspheres in patients with advanced hepatocellular carcinoma and portal vein thrombosis.
  • PURPOSE: Patients with portal vein thrombosis (PVT) and hepatocellular carcinoma (HCC) have limited treatment options because of increased disease burden and diminished hepatic perfusion.

  • Genetic Alliance. consumer health - Portal thrombosis.
  • Genetic Alliance. consumer health - Portal vein thrombosis.
  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 SIR. Published by Elsevier Inc. All rights reserved.
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Hepatology. 2000 Aug;32(2):233-8 [10915729.001]
  • [Cites] Cancer. 2000 Dec 1;89(11):2266-73 [11147597.001]
  • [Cites] Gut. 2002 Jun;50(6):881-5 [12010894.001]
  • [Cites] J Vasc Interv Radiol. 2002 Sep;13(9 Pt 2):S211-21 [12354839.001]
  • [Cites] J Vasc Interv Radiol. 2002 Sep;13(9 Pt 2):S223-9 [12354840.001]
  • [Cites] J Vasc Interv Radiol. 2004 Apr;15(4):335-45 [15064336.001]
  • [Cites] J Nucl Med. 1971 Mar;:Suppl 5:5-23 [5551700.001]
  • [Cites] J Vasc Interv Radiol. 1993 May-Jun;4(3):347-51 [8513208.001]
  • [Cites] Eur J Nucl Med. 1997 Mar;24(3):293-8 [9143467.001]
  • [Cites] J Cancer Res Clin Oncol. 1998;124(7):397-400 [9719503.001]
  • [Cites] Hepatology. 1998 Sep;28(3):751-5 [9731568.001]
  • [Cites] Hepatology. 1999 Jan;29(1):62-7 [9862851.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Cancer. 2005 Jun 1;103(11):2419-26 [15822130.001]
  • [Cites] Am J Gastroenterol. 2005 Sep;100(9):1995-2004 [16128944.001]
  • [Cites] J Vasc Interv Radiol. 2005 Dec;16(12):1653-9 [16371532.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):412-25 [16690429.001]
  • [Cites] Cardiovasc Intervent Radiol. 2006 Jul-Aug;29(4):522-9 [16729228.001]
  • [Cites] J Vasc Interv Radiol. 2006 Aug;17(8):1251-78 [16923973.001]
  • [Cites] World J Gastroenterol. 2006 Dec 21;12(47):7561-7 [17171782.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):13-23 [17448867.001]
  • [Cites] Dig Dis Sci. 2007 Nov;52(11):3290-5 [17394062.001]
  • [Cites] Hepatology. 2008 Jan;47(1):71-81 [18027884.001]
  • [Cites] Drugs. 2008;68(2):251-8 [18197728.001]
  • [Cites] Oncology. 2007;72(3-4):188-93 [18097170.001]
  • [Cites] Liver Int. 2009 Jan;29(1):74-81 [18331238.001]
  • [Cites] J Am Coll Surg. 2009 Mar;208(3):375-82 [19317999.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Aug 1;74(5):1494-500 [19157721.001]
  • (PMID = 20691606.001).
  • [ISSN] 1535-7732
  • [Journal-full-title] Journal of vascular and interventional radiology : JVIR
  • [ISO-abbreviation] J Vasc Interv Radiol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K23 CA118431-02; United States / NCI NIH HHS / CA / CA118431-04; United States / NCI NIH HHS / CA / K23 CA118431-05; United States / NCI NIH HHS / CA / K23 CA118431; United States / NCI NIH HHS / CA / K23 CA118431-01A1; United States / NCI NIH HHS / CA / CA118431-02; United States / NCI NIH HHS / CA / CA118431-03; United States / NCI NIH HHS / CA / K23 CA118431-04; United States / NCI NIH HHS / CA / CA118431-05; United States / NCI NIH HHS / CA / K23 CA118431-03
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0 / Yttrium Radioisotopes
  • [Other-IDs] NLM/ NIHMS227449; NLM/ PMC2945527
  •  go-up   go-down


76. Oishi K, Itamoto T, Amano H, Fukuda S, Ohdan H, Tashiro H, Shimamoto F, Asahara T: Clinicopathologic features of poorly differentiated hepatocellular carcinoma. J Surg Oncol; 2007 Mar 15;95(4):311-6
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features of poorly differentiated hepatocellular carcinoma.
  • BACKGROUND AND OBJECTIVES: Clinicopathologic features of poorly differentiated hepatocellular carcinoma (HCC) have not been elucidated.
  • CONCLUSIONS: Poorly differentiated HCC tumors larger than 3 cm are already of advanced stage representing distant metastasis in the early period after hepatectomy.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Differentiation. Female. Hepatectomy. Humans. Male. Middle Aged. Prospective Studies. Survival Rate. alpha-Fetoproteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17326126.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


77. Kang YK, Hong SW, Lee H, Kim WH: Prognostic implications of ezrin expression in human hepatocellular carcinoma. Mol Carcinog; 2010 Sep;49(9):798-804
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic implications of ezrin expression in human hepatocellular carcinoma.
  • The authors investigated ezrin expression in human hepatocellular carcinoma (HCC) and sought to determine its relation with clinicopathologic parameters, patients' outcome, and interacting molecular markers.
  • HCCs expressing high level of ezrin were significantly associated with advanced TNM stage, poor Edmondson's histological grade, macroscopic portal vein invasion, tumor recurrence, and extrahepatic recurrence (P < 0.05).
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Carcinoma, Hepatocellular / pathology. Liver Neoplasms / metabolism. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers / metabolism. Cadherins. Cytoskeletal Proteins. Disease Progression. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasms / pathology. Prognosis. Young Adult


78. Balsom SM, Li X, Trolli E, Rose J, Bloomston M, Patel T, Bekaii-Saab TS: A single-institute experience with sorafenib in untreated and previously treated patients with advanced hepatocellular carcinoma. Oncology; 2010;78(3-4):210-2
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A single-institute experience with sorafenib in untreated and previously treated patients with advanced hepatocellular carcinoma.
  • OBJECTIVES: Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide.
  • Sorafenib is considered the standard of care for patients with advanced HCC.
  • METHODS: We conducted a retrospective analysis of our cancer center's experience with sorafenib in patients with advanced HCC.
  • CONCLUSION: Sorafenib has interesting activity and acceptable tolerability in patients with advanced HCC, including those who failed prior therapies.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Pyridines / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Male. Medical Oncology / methods. Middle Aged. Niacinamide / analogs & derivatives. Phenylurea Compounds. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20424492.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


79. Zhu Lz, Yang Rj: [Digital subtraction angiography manifestation and interventional therapy of arteriovenous shunting in primary hepatocellular carcinoma of advanced stage]. Beijing Da Xue Xue Bao; 2008 Apr;40(2):129-34
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Digital subtraction angiography manifestation and interventional therapy of arteriovenous shunting in primary hepatocellular carcinoma of advanced stage].
  • OBJECTIVE: To explore the appearances of digital subtraction angiography (DSA) and therapeutic efficacy of interventional therapy of hepatic carcinoma accompanied with arteriovenous shunting (AVS).
  • METHODS: To retrospectively analyze clinical material of 97 patients with hepatocellular carcinoma with hepatic artery-portal vein shunting(HA-PVS), of whom, 16 had upper gastrointestinal hemorrhage, 51 had middle to large amounts of ascites, and 53 had varices of esophagus and fundus gastricus.
  • CONCLUSION: Primary hepatic carcinoma with AVS increases difficulty of interventional therapyìbut as long as we take active and proper treating measureìwe could acquire satisfactory curative effect without serious syndrome.
  • DSA can demonstrate the type, the site and the degree of AVS completely and directly, thus having important value in treating primary hepatic carcinoma and improving prognosis.
  • [MeSH-minor] Adult. Aged. Carcinoma, Hepatocellular / complications. Carcinoma, Hepatocellular / radiography. Female. Hepatic Artery / abnormalities. Humans. Male. Middle Aged. Portal Vein / abnormalities. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18458684.001).
  • [ISSN] 1671-167X
  • [Journal-full-title] Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  • [ISO-abbreviation] Beijing Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


80. Nagata H, Hatano E, Asechi H, Narita M, Yanagida A, Yasuchika K, Ikai I, Uemoto S: [Retrospective analysis of clinical results in eight patients with advanced hepatocellular carcinoma with lung metastases treated by TS-1]. Gan To Kagaku Ryoho; 2007 Feb;34(2):233-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Retrospective analysis of clinical results in eight patients with advanced hepatocellular carcinoma with lung metastases treated by TS-1].
  • Advanced hepatocellular carcinoma (HCC) with distant metastases, in particular to the lung, has a poor prognosis.
  • This study was undertaken to evaluate the effectiveness of TS-1 as chemotherapy in advanced HCC with lung metastases.
  • Between January 2004 and October 2005, 8 patients with advanced HCC with lung metastasis were enrolled.
  • Randomized controlled trials are necessary to clarify survival benefits in patients with advanced HCC with lung metastasis.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Lung Neoplasms / secondary. Oxonic Acid / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Drug Combinations. Female. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17301534.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


81. Becker G, Schmitt-Graeff A, Ertelt V, Blum HE, Allgaier HP: CD117 (c-kit) expression in human hepatocellular carcinoma. Clin Oncol (R Coll Radiol); 2007 Apr;19(3):204-8
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD117 (c-kit) expression in human hepatocellular carcinoma.
  • AIMS: Although various methods of treatment have been tried, treatment options for advanced hepatocellular carcinoma (HCC) remain limited.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Liver Neoplasms / metabolism. Proto-Oncogene Proteins c-kit / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Benzamides. Child. Female. Humans. Imatinib Mesylate. Immunohistochemistry. Male. Middle Aged. Piperazines / pharmacology. Piperazines / therapeutic use. Pyrimidines / pharmacology. Pyrimidines / therapeutic use. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17359908.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


82. Snowberger N, Chinnakotla S, Lepe RM, Peattie J, Goldstein R, Klintmalm GB, Davis GL: Alpha fetoprotein, ultrasound, computerized tomography and magnetic resonance imaging for detection of hepatocellular carcinoma in patients with advanced cirrhosis. Aliment Pharmacol Ther; 2007 Nov 1;26(9):1187-94
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alpha fetoprotein, ultrasound, computerized tomography and magnetic resonance imaging for detection of hepatocellular carcinoma in patients with advanced cirrhosis.
  • BACKGROUND: Serum alpha fetoprotein (AFP), ultrasound, computerized tomography scanning, and magnetic resonance imaging are commonly used to screen for hepatocellular carcinoma (HCC) in patients with cirrhosis.
  • AIM: To assess the accuracy of screening in advanced cirrhosis.
  • RESULTS: Hepatocellular carcinoma was detected before liver transplant in 78% and discovered incidentally in 22%.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Liver Cirrhosis / diagnosis. Liver Neoplasms / diagnosis. alpha-Fetoproteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Liver Transplantation. Magnetic Resonance Imaging. Male. Middle Aged. Retrospective Studies. Sensitivity and Specificity. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17944733.001).
  • [ISSN] 0269-2813
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


83. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol; 2009 Jan;10(1):25-34
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
  • BACKGROUND: Most cases of hepatocellular carcinoma occur in the Asia-Pacific region, where chronic hepatitis B infection is an important aetiological factor.
  • We did a multinational phase III, randomised, double-blind, placebo-controlled trial to assess the efficacy and safety of sorafenib in patients from the Asia-Pacific region with advanced (unresectable or metastatic) hepatocellular carcinoma.
  • METHODS: Between Sept 20, 2005, and Jan 31, 2007, patients with hepatocellular carcinoma who had not received previous systemic therapy and had Child-Pugh liver function class A, were randomly assigned to receive either oral sorafenib (400 mg) or placebo twice daily in 6-week cycles, with efficacy measured at the end of each 6-week period.
  • INTERPRETATION: Sorafenib is effective for the treatment of advanced hepatocellular carcinoma in patients from the Asia-Pacific region, and is well tolerated.
  • Taken together with data from the Sorafenib Hepatocellular Carcinoma Assessment Randomised Protocol (SHARP) trial, sorafenib seems to be an appropriate option for the treatment of advanced hepatocellular carcinoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Protein Kinase Inhibitors / therapeutic use. Pyridines / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cost-Benefit Analysis. Double-Blind Method. Female. Humans. Male. Middle Aged. Niacinamide / analogs & derivatives. Phenylurea Compounds

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gastroenterology. 2009 Sep;137(3):1171-3 [19632249.001]
  • [CommentIn] Lancet Oncol. 2009 Jan;10(1):4-5 [19111238.001]
  • (PMID = 19095497.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00492752
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


84. Tang TC, Poon RT, Lau CP, Xie D, Fan ST: Tumor cyclooxygenase-2 levels correlate with tumor invasiveness in human hepatocellular carcinoma. World J Gastroenterol; 2005 Apr 7;11(13):1896-902
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor cyclooxygenase-2 levels correlate with tumor invasiveness in human hepatocellular carcinoma.
  • Although COX-2 expression has been demonstrated in hepatocellular carcinoma (HCC), the significance of COX-2 in progression of HCC remains unclear.
  • Correlation with clinicopathological features showed significantly higher tumor cytosolic COX-2 levels in the presence of multiple tumors (P = 0.027), venous invasion (P = 0.030), microsatellite lesions (P = 0.037) and advanced tumor stage (P = 0.008).
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Carcinoma, Hepatocellular / pathology. Liver Neoplasms / metabolism. Liver Neoplasms / pathology. Prostaglandin-Endoperoxide Synthases / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Cyclooxygenase 2. Cytosol / enzymology. Female. Humans. Male. Membrane Proteins. Middle Aged. Neoplasm Invasiveness. Prognosis. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15800977.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Proteins; 0 / Vascular Endothelial Growth Factor A; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  • [Other-IDs] NLM/ PMC4305708
  •  go-up   go-down


85. Zhang L, Fan WJ, Huang JH, Li CX, Zhao M, Wang LG, Tang T: Comprehensive sequential interventional therapy for hepatocellular carcinoma. Chin Med J (Engl); 2009 Oct 5;122(19):2292-8
Hazardous Substances Data Bank. ETHANOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comprehensive sequential interventional therapy for hepatocellular carcinoma.
  • This study aimed to evaluate the effectiveness of comprehensive sequential interventional therapy especially personal therapeutic plan in 53 radical cure patients with hepatocellular carcinoma (HCC).
  • CONCLUSION: Comprehensive sequential interventional therapy especially personal therapeutic plan for HCC play roles in interventional treatment of HCC in middle or advanced stage.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Catheter Ablation. Chemoembolization, Therapeutic. Combined Modality Therapy. Ethanol / administration & dosage. Female. Humans. Male. Middle Aged. Positron-Emission Tomography. Tomography, X-Ray Computed. Ultrasonic Therapy

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20079128.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 3K9958V90M / Ethanol
  •  go-up   go-down


86. Lee WC, Wang HC, Hung CF, Huang PF, Lia CR, Chen MF: Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. J Immunother; 2005 Sep-Oct;28(5):496-504
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial.
  • Hepatocellular carcinoma (HCC) is a common and rapidly progressing malignancy.
  • Current treatment options for advanced HCC are limited.
  • This clinical study of dendritic cell (DC)-based immunotherapy for HCC enrolled 31 patients with advanced HCC.
  • In this trial, DC vaccinations for advanced HCC were safe.
  • Pulsed DC vaccination followed by boosters can provide better clinical survival for advanced HCC patients than pulsed DC vaccination only.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Dendritic Cells / cytology. Immunotherapy / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cancer Vaccines. Cell Membrane / metabolism. Cytokines / metabolism. Disease Progression. Female. Humans. Hypersensitivity, Delayed. Immunotherapy, Adoptive / methods. Lymphocytes / metabolism. Male. Middle Aged. Monocytes / cytology. Phenotype. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16113606.001).
  • [ISSN] 1524-9557
  • [Journal-full-title] Journal of immunotherapy (Hagerstown, Md. : 1997)
  • [ISO-abbreviation] J. Immunother.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Cytokines
  •  go-up   go-down


87. Hernández-Castillo E, Mondragón-Sánchez R, Garduno-Lopez AL, Gómez-Gómez E, Ruiz-Molina JM, Oñate-Ocaña LF, Bernal-Maldonado R: Hepatocellular carcinoma in the youth. A comparative analysis with hepatocellular carcinoma in adulthood. Hepatogastroenterology; 2005 May-Jun;52(63):903-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma in the youth. A comparative analysis with hepatocellular carcinoma in adulthood.
  • BACKGROUND/AIMS: Hepatocellular carcinoma (HCC) is a very rare disease among young individuals.
  • It is discovered at an advanced stage.
  • The frequency of fibrolamellar carcinoma is higher in this age group.
  • [MeSH-major] Carcinoma, Hepatocellular / epidemiology. Liver Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Child. Cross-Sectional Studies. Diagnosis, Differential. Disease-Free Survival. Female. Hepatectomy. Humans. Incidence. Liver Function Tests. Male. Middle Aged. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15966229.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


88. Ho JW, Pang RW, Lau C, Sun CK, Yu WC, Fan ST, Poon RT: Significance of circulating endothelial progenitor cells in hepatocellular carcinoma. Hepatology; 2006 Oct;44(4):836-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of circulating endothelial progenitor cells in hepatocellular carcinoma.
  • This study evaluated the significance of circulating bone marrow-derived endothelial progenitor cells (EPCs) in patients with hepatocellular carcinoma (HCC), a solid tumor with rich neovasculature.
  • In conclusion, higher circulating levels of EPCs are seen in patients with advanced unresectable HCC as compared to patients with resectable HCC or those with liver cirrhosis.
  • [MeSH-major] Carcinoma, Hepatocellular / blood. Endothelial Cells. Liver Neoplasms / blood. Stem Cells
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Female. Humans. Interleukin-8 / blood. Male. Middle Aged. Vascular Endothelial Growth Factor A / blood. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17006919.001).
  • [ISSN] 0270-9139
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-8; 0 / Vascular Endothelial Growth Factor A; 0 / alpha-Fetoproteins
  •  go-up   go-down


89. Shao YY, Lin ZZ, Hsu C, Shen YC, Hsu CH, Cheng AL: Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer; 2010 Oct 1;116(19):4590-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma.
  • BACKGROUND: Antiangiogenic therapy has become the most important treatment modality for patients with advanced hepatocellular carcinoma (HCC).
  • METHODS: Patients with advanced HCC who had been enrolled in 3 prospective phase 2 clinical trials that evaluated either sorafenib, bevacizumab, or thalidomide in combination with a potentially antiangiogenic, metronomic, oral 5-fluoropyrimidine as first-line systemic therapy were included.
  • CONCLUSIONS: The current results indicated that an early AFP response is a useful surrogate marker to predict treatment response and prognosis in patients with advanced HCC who receive antiangiogenic therapy.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / metabolism. Liver Neoplasms / drug therapy. Liver Neoplasms / metabolism. alpha-Fetoproteins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Cancer Society.
  • (PMID = 20572033.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Biomarkers, Tumor; 0 / alpha-Fetoproteins
  •  go-up   go-down


90. Wang D, Dou K, Xiang H, Song Z, Zhao Q, Chen Y, Li Y: Involvement of RhoA in progression of human hepatocellular carcinoma. J Gastroenterol Hepatol; 2007 Nov;22(11):1916-20
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involvement of RhoA in progression of human hepatocellular carcinoma.
  • The clinicopathological significance of RhoA, however, is not yet well known in the case of hepatocellular carcinoma (HCC).
  • With regard to venous invasion, satellite lesions and advanced pTNM stage, the RhoA level tended to be higher in HCC than that seen in negative tissue (P < 0.05).
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Hepatocellular / enzymology. Liver Neoplasms / enzymology. rhoA GTP-Binding Protein / analysis
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Neoplasm Staging. Polymerase Chain Reaction. RNA, Messenger / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17914970.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 124671-05-2 / RHOA protein, human; EC 3.6.5.2 / rhoA GTP-Binding Protein
  •  go-up   go-down


91. Chen SX, Xu WD, Yin GW, Xi W, Chen J, Xu QY, Ma GJ: [Clinical therapeutic effect and biological monitoring of p53 gene in advanced hepatocellular carcinoma]. Zhonghua Yi Xue Za Zhi; 2010 Aug 17;90(31):2182-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical therapeutic effect and biological monitoring of p53 gene in advanced hepatocellular carcinoma].
  • OBJECTIVE: To investigate the therapeutic effect and biological changes of hepatic arterial perfusion of p53 gene via port catheter system (PCS) on advanced hepatocellular carcinoma.
  • METHODS: A total of 48 cases of advanced hepatocellular carcinoma were divided into the experimental group (30) and the control group (18).
  • CONCLUSION: p53 gene sequential infusion via hepatic artery is effective for advanced hepatocellular carcinoma.
  • [MeSH-major] Carcinoma, Hepatocellular / drug therapy. Genes, p53. Genetic Therapy. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Survival Rate. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21029657.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] Controlled Clinical Trial; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


92. Lim TY, Cheong JY, Cho SW, Sim SJ, Kim JS, Choi SJ, Choi JW, Kwon HC, Lee KM, Kim JK, Won JH, Yoo BM, Lee KJ, Hahm KB, Kim JH: [Effect of low dose 5-fluorouracil and cisplatin intra-arterial infusion chemotherapy in advanced hepatocellular carcinoma with decompensated cirrhosis]. Korean J Hepatol; 2006 Mar;12(1):65-73
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of low dose 5-fluorouracil and cisplatin intra-arterial infusion chemotherapy in advanced hepatocellular carcinoma with decompensated cirrhosis].
  • BACKGROUND/AIMS: Advanced hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) has a poor prognosis.
  • The aim of this study was to evaluate the efficacy and safety of repeated arterial infusions of low dose cisplatin and 5-fluorouracil (FU) in patients with advanced HCC with decompensated cirrhosis.
  • CONCLUSIONS: Intra-arterial chemotherapy consisting of low dose 5-FU and cisplatin achieved favorable results for advanced HCC patients who had decompensated cirrhosis, and it showed better survival in selected patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Infusions, Intra-Arterial. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Humans. Liver Cirrhosis / complications. Male. Middle Aged. Palliative Care. Portal Vein. Survival Rate. Venous Thrombosis / complications

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16565607.001).
  • [ISSN] 1738-222X
  • [Journal-full-title] The Korean journal of hepatology
  • [ISO-abbreviation] Korean J Hepatol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


93. Vora SR, Zheng H, Stadler ZK, Fuchs CS, Zhu AX: Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma. Oncologist; 2009 Jul;14(7):717-25
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma.
  • BACKGROUND: The role of serum alpha-fetoprotein (AFP) as a marker for treatment response in patients with hepatocellular carcinoma (HCC) receiving systemic therapy is poorly defined.
  • METHODS: A retrospective study was performed on patients with advanced HCC enrolled in five phase II clinical trials.
  • CONCLUSIONS: Our study suggests that serum AFP change during treatment may serve as a useful surrogate marker for clinical outcome in patients with advanced HCC receiving systemic therapy.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Hepatocellular / blood. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / blood. Liver Neoplasms / drug therapy. alpha-Fetoproteins / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Clinical Trials as Topic / methods. Disease-Free Survival. Humans. Male. Middle Aged. Multivariate Analysis. Retrospective Studies. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19581525.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / alpha-Fetoproteins
  •  go-up   go-down


94. Li YY, Sha WH, Zhou YJ, Nie YQ: Short and long term efficacy of high intensity focused ultrasound therapy for advanced hepatocellular carcinoma. J Gastroenterol Hepatol; 2007 Dec;22(12):2148-54
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short and long term efficacy of high intensity focused ultrasound therapy for advanced hepatocellular carcinoma.
  • BACKGROUND: The aim of this study was to investigate the short and long term efficacy of high intensity focused ultrasound therapy (HIFU) in patients with advanced hepatocellular carcinoma (HCC).
  • CONCLUSION: HIFU is an effective and safe ablation therapy with satisfactory short and long term efficacy for patients with advanced HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Liver Neoplasms / therapy. Ultrasonic Therapy / methods
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Demography. Female. Humans. Karnofsky Performance Status. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Survival Rate. Time Factors. Treatment Outcome. alpha-Fetoproteins

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18031373.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


95. Liang HL, Huang JS, Lin YH, Lai KH, Yang CF, Pan HB: Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma by placing a temporary catheter via the subclavian route. Acta Radiol; 2007 Sep;48(7):734-40
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma by placing a temporary catheter via the subclavian route.
  • BACKGROUND: A permanent reservoir implantation is considered mandatory for hepatic arterial infusion chemotherapy (HAIC) of hepatocellular carcinoma (HCC).
  • PURPOSE: To evaluate the feasibility of placing a temporary catheter for HAIC in advanced HCC patients.
  • MATERIAL AND METHODS: 25 advanced HCC patients underwent HAIC with drugs delivered from a temporary catheter which was placed percutaneously by puncturing the left subclavian artery under ultrasound guidance.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / administration & dosage. Catheters, Indwelling. Drug Administration Schedule. Feasibility Studies. Follow-Up Studies. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17729003.001).
  • [ISSN] 0284-1851
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


96. Jhawer M, Rosen L, Dancey J, Hochster H, Hamburg S, Tempero M, Clendeninn N, Mani S: Phase II trial of nolatrexed dihydrochloride [Thymitaq, AG 337] in patients with advanced hepatocellular carcinoma. Invest New Drugs; 2007 Feb;25(1):85-94
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of nolatrexed dihydrochloride [Thymitaq, AG 337] in patients with advanced hepatocellular carcinoma.
  • BACKGROUND: To evaluate the tolerability and efficacy of nolatrexed in patients with advanced hepatocellular carcinoma.
  • CONCLUSION: This phase II study of nolatrexed in advanced HCC patients, demonstrated minimal activity and significant stomatitis.
  • [MeSH-major] Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Quinazolines / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antimetabolites, Antineoplastic / adverse effects. Antimetabolites, Antineoplastic / pharmacokinetics. Antimetabolites, Antineoplastic / therapeutic use. Drug Administration Schedule. Exanthema / chemically induced. Female. Humans. Infusions, Intravenous. Male. Metabolic Clearance Rate. Middle Aged. Nausea / chemically induced. Stomatitis / chemically induced. Survival Analysis. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16957834.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Quinazolines; K75ZUN743Q / nolatrexed
  •  go-up   go-down


97. Natsuizaka M, Omura T, Akaike T, Kuwata Y, Yamazaki K, Sato T, Karino Y, Toyota J, Suga T, Asaka M: Clinical features of hepatocellular carcinoma with extrahepatic metastases. J Gastroenterol Hepatol; 2005 Nov;20(11):1781-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features of hepatocellular carcinoma with extrahepatic metastases.
  • BACKGROUND: There are few detailed clinical reports about extrahepatic metastases of hepatocellular carcinoma (HCC).
  • RESULTS: Patients with extrahepatic metastases had more advanced intrahepatic tumors at the first diagnosis of HCC: 73.8% of the patients with extrahepatic metastases had tumors of intrahepatic tumor stage T3 or T4 according to the TNM classification, while only 28.5% of the patients without extrahepatic metastases had tumors of T3 or T4 (P < 0.001).
  • The possibility of extrahepatic metastases and the clinical features of extrahepatic metastases should be considered when examining patients with HCC, particularly those with advanced intrahepatic tumors, to enable precise evaluation of the spread of HCC and determination of the appropriate treatment method.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / secondary. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Neoplasms / complications. Bone Neoplasms / secondary. Bone Neoplasms / therapy. Brain Neoplasms / complications. Brain Neoplasms / secondary. Brain Neoplasms / therapy. Disease Progression. Female. Hepatitis, Viral, Human. Humans. Lung Neoplasms / complications. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Blackwell Publishing Asia Pty Ltd.
  • (PMID = 16246200.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


98. Zhao M, Wang JP, Wu PH, Zhang FJ, Huang ZL, Li W, Zhang L, Pan CC, Li CX, Jiang Y: [Comparative analysis of TACE alone or plus RFA in the treatment of 167 cases of intermediate and advanced staged primary hepatocellular carcinoma]. Zhonghua Yi Xue Za Zhi; 2010 Nov 9;90(41):2916-21
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparative analysis of TACE alone or plus RFA in the treatment of 167 cases of intermediate and advanced staged primary hepatocellular carcinoma].
  • OBJECTIVE: To evaluate the clinical efficacy and survival rate of transarterial chemoembolization (TACE) alone or plus radiofrequency ablation (RFA) in patients with intermediate or advanced stage primary hepatocellular carcinoma (HCC).
  • For the advanced stage HCC, the median survival time was 12 months, one-year survival rate 35%, three-year survival rate 7.1% and five-year survival rate 0 in the TACE alone group versus 28 months, 62.1%, 24.1% and 6.9% in the TACE plus RFA group (P = 0.00).
  • There was significantly statistic difference between both groups in intermediate and advanced staging HCC.
  • CONCLUSION: The regimen of TACE plus RFA has the advantages of tumor control, liver function protection and survival extending in the treatment of HCC than TACE alone in intermediate or advanced stage HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Catheter Ablation. Embolization, Therapeutic. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21211397.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


99. Lu X, Zhao HT, Mao YL, Sang XT, Xu YY, Du SD, Xu HF, Chi TY, Yang ZY, Zhong SX, Huang JF: [Early recurrence after the resection of hepatocellular carcinoma]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Aug;30(4):415-20
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Early recurrence after the resection of hepatocellular carcinoma].
  • OBJECTIVE: To observe the precise time of the recurrence after resection of hepatocellular carcinoma (HCC) and to further explore the risk factors associated with postoperative recurrence.
  • CONCLUSIONS: Most recurrences occure within the first six months postoperatively and multifocal carcinogenesis is one of the risk factors associated with early recurrence after liver resection for advanced HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / surgery. Liver Neoplasms / pathology. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Hepatectomy. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Postoperative Period. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18795612.001).
  • [ISSN] 1000-503X
  • [Journal-full-title] Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • [ISO-abbreviation] Zhongguo Yi Xue Ke Xue Yuan Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


100. Cohn AL, Myers JW, Mamus S, Deur C, Nicol S, Hood K, Khan MM, Ilegbodu D, Asmar L: A phase II study of pemetrexed in patients with advanced hepatocellular carcinoma. Invest New Drugs; 2008 Aug;26(4):381-6
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of pemetrexed in patients with advanced hepatocellular carcinoma.
  • Pemetrexed has demonstrated activity in hepatocellular carcinoma (HCC) cell lines, and has a manageable toxicity profile in clinical trials, suggesting its potential as a treatment for HCC patients.
  • A multicenter, Phase II community-based study was conducted to assess the response rate and toxicity profile of single-agent pemetrexed in first-line patients with advanced or metastatic HCC.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Glutamates / therapeutic use. Guanine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dexamethasone / therapeutic use. Disease Progression. Female. Folic Acid / therapeutic use. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Pemetrexed. Survival Rate. Treatment Outcome. Vitamin B 12 / therapeutic use

  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. FOLIC ACID .
  • Hazardous Substances Data Bank. CYANOCOBALAMIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18305899.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; 7S5I7G3JQL / Dexamethasone; 935E97BOY8 / Folic Acid; P6YC3EG204 / Vitamin B 12
  •  go-up   go-down






Advertisement